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ABSTRACT 
 
Jason Paul Seifert 
Regulation of Phospholipase C-epsilon by Rho and Ras Family Proteins 
(Under the direction of Dr. T. Kendall Harden) 
 
 Inositol phospholipids are a unique collection of signaling molecules involved in 
an extensive variety of signaling events including actin remodeling, membrane 
trafficking, and calcium mobilization.  Phosphoinositides regulate signaling responses by 
binding specific effector proteins, or through the generation of second messenger 
molecules.  The most well characterized phosphoinositide signaling pathway is the 
hydrolysis of phosphatidylinositol (4,5)-bisphosphate by the phospholipase C (PLC) 
family of enzymes.  PLCs cleaves the inositol headgroup from the glycerol backbone of 
PtdIns(4,5)P2, generating the second messenger molecules inositol (1,4,5)-trisphosphate 
and diacylglycerol.  An extensive array of extracellular signaling molecules elicit their 
physiological effects through receptor-mediated stimulation of PLC isozymes.  All PLC 
enzymes contain a conserved catalytic region; however, elaboration of the catalytic core 
with various protein binding and/or regulatory domains gives rise to multiple modes of 
regulation and different PLC subfamilies.  Recent work has implicated Ras superfamily 
GTPases in the regulation of several PLC isoforms adding a new level of complexity to 
phosphoinositide metabolism. 
 Phospholipase C-epsilon (PLC-ε) is an elaborate PLC isoform that is regulated by 
several signaling pathways, including downstream of both heterotrimeric and Ras 
superfamily GTPases.  The work described herein examines the regulation of PLC-ε 
iv 
enzyme activity through direct interactions with Ras superfamily GTPases.  We describe the 
purification and functional characterization of a catalytically active fragment of PLC-ε with 
the goal of providing incontrovertible evidence regarding direct Rho and Ras family 
regulation of enzyme activity.  Reconstitution of purified proteins in model phospholipid 
vesicles demonstrates RhoA and K-Ras individually are sufficient to increase the activity of 
PLC-ε in both a concentration- and GTPγS-dependent manner.  Moreover, RhoA and K-Ras 
required mutually exclusive sites of interaction to confer increased PLC-ε activity.  Finally, 
when maximally activated by RhoA or K-Ras, PLC-ε activity is increased further by the 
addition of the complementary GTPase, and the enzyme displayed increased sensitivity to K-
Ras in the presence of a maximally activating concentration of RhoA.  These results identify 
PLC-ε as a novel enzyme that is regulated by Rho and Ras family GTPases through distinct 
domains, leading to individual and dual regulation of enzyme activity. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 The Basis of Cell Signaling 
 The essential function of any cell, whether a single-celled organism or a member of a 
multicellular organism, is to increase the chances of overall survival by adapting to 
environmental changes.  Throughout evolution, innumerable mechanisms have arisen 
whereby cells recognize extracellular chemicals via cell surface “detectors”, which transduce 
information across the membrane and initiate intracellular signaling cascades.  In mammals, 
the most extensively characterized signaling pathways involve the release of hormones, 
neurotransmitters, growth factors, and other signaling molecules, leading to the activation of 
transmembrane receptors and subsequent downstream alterations in cellular processes. 
Whereas signal transduction pathways were once believed to be relatively simple and linear 
in nature, the discovery of signaling networks has altered this classical view of cell signaling.  
Crosstalk between virtually all signaling pathways results in complex mechanisms regulating 
the homeostasis of nearly every cell within an organism.   
1.2 Inositol Phospholipids 
 A family of inositol-containing glycerophospholipids, the inositol phospholipids 
(PIs), make up a diverse subset of signaling molecules involved in a wide variety of signaling 
events.  Eight naturally occurring inositol phospholipids have been identified, seven of which 
are phosphorylated in varying combinations at one or more of the free hydroxyl groups of the 
 inositol ring.  Inositol phospholipids elicit signaling responses through the generation of 
second messenger molecules or by binding specific effector proteins, which in turn control 
several signaling events including actin remodeling, membrane trafficking, and ion channel 
function.  Inositol phospholipid metabolism is controlled by a family of PI-kinases and PI-
phosphatases, as well as hydrolysis of phosphoinositides by phospholipase C enzymes. 
1.2.1 Structure and Metabolism of Inositol Phospholipids 
Inositol phospholipids are comprised of a diacylglycerol (DAG) lipid moiety and an 
exposed inositol headgroup (Figure 1.1).  The fatty acid chains of the DAG lipid moiety 
mediate the localization of PIs to various cellular membranes, whereas the polar headgroup is 
exposed and recognized by distinct phosphatidylinositol-specific binding proteins or 
phospholipase enzymes. Phosphatidylinositol synthase attaches D-myo-inositol to CDP-DAG 
through a di-ester phosphate bond at the D-1 position of the inositol ring [1].  The end 
product of the synthesis reaction is phosphatidylinositol (PtdIns), the building block of all 
inositol phospholipids.  Attachment of  DAG at the 6-position of the D-myo-inositol ring 
leaves five free hydroxyl groups, three of which are progressively phosphorylated at the 3-, 
4-, and/or 5-positions, giving rise to seven naturally occurring phosphoinositides.   
Lipid kinases recognize and phosphorylate PtdIns by catalyzing the transfer of a γ-
phosphate from ATP to specific locations on the inositol headgroup of PtdIns.  The 
nomenclature of phosphatidylinositol kinases and phosphatidylinositol phosphate kinases is 
derived from the position on the inositol ring phosphorylated by a specific kinase.  For 
example, PI 3-K phosphorylates the inositol ring at the 3-position of PtdIns to form 
PtdIns(3)P, whereas PI(4)P 5-K recognizes PtdIns(4)P and phosphorylates the 5-hydroxyl 
group to form PtdIns(4,5)P2 [2].  The action of lipid kinases is antagonized by two major 
2
 classes of inositol lipid phosphatases, which remove phosphate groups from specific 
positions on the inositol ring.   PTEN (Phosphatase and TENsin homologue deleted on 
chromosome TEN) and SHIP (SH2-containing Inositol Phophatase) are inositol lipid 
phosphatases with 3- and 5-position phosphatase activity, respectively [3;4].    
 Through various combinations of PtdIns phosphorylation and dephosphorylation, 
lipid kinases and phosphatases create seven species of phosphoinositides.  PtdIns is the most 
abundant inositol lipid in mammalian cells, with levels 10-20 times greater than PtdIns(4)P 
or PtdIns(4,5)P2.  PtdIns(4)P represents approximately 95% of the total singly 
phosphorylated PtdIns in cells, with PtdIns(3)P and PtdIns(5)P representing the additional 
5% in roughly equal proportions.  PtdIns(4,5)P2 constitutes more than  99% of doubly 
phosphorylated PtdIns in cells, and represents about 1% of total phospholipids in resting 
cells.  The other two PtdInsP2 species, PtdIns(3,5)P2 and PtdIns(3,4)P2, each constitute about 
0.2% of doubly phosphorylated lipids.  The only trisphosphoinositide, PtdIns(3,4,5)P3, exists 
in the cells at varying concentrations; however, levels are typically low, in a similar range of 
PtdIns(3,4)P2 and PtdIns(3,5)P2 (lipid levels reviewed [4-6]).  
1.3  Phosphoinositide Binding Domains 
A diverse set of protein domains bind phosphoinositides promoting directed 
translocation to the plasma membrane and/or regulation of protein function.  Proteins with 
phosphoinositide binding domains are implicated in various cell signaling events, including 
intracellular trafficking, cytoskeletal remodeling, and receptor promoted signal transduction 
[7].  Phosphoinositides also regulate several ion channels and transporters, but knowledge 
regarding the mechanisms governing phosphoinositide regulation of these proteins is limited 
[8].  Continuous changes in the relative concentrations of different phospholipids, and 
3
 variable organelle membrane compositions regulate a myriad of signaling pathways through 
localized recruitment of phospholipid-binding proteins. 
1.3.1 PtdIns(4,5)P2 Binding Domains 
PH Domains 
 The human genome encodes over 250 PH (pleckstrin homology) domains, the 
eleventh most common domain in the human proteome.  Several proteins involved in cellular 
signaling, cytoskeletal organization, membrane trafficking and/or phospholipid modification 
contain PH domains [9-11].  Sequence conservation among PH domains is only 7-30%; 
however, PH domains are defined by conserved secondary structural elements [9;12].  
Approximately 120 amino acids in length, PH domains fold into a small seven-stranded β-
sandwich core, capped at one end by a carboxy-terminal α-helix and by three interstranded 
loops at the other end [12].  These three interstranded loops are highly variable among PH 
domains and are implicated in the potential binding of phosphoinositides.  Indeed, many PH 
domains bind phosphoinositides, albeit with poor specificity and low affinity [13].  
Alternatively, certain PH domains, such as those that bind PtdIns(3,4,5)P3, and the PH 
domain of PLC-δ1, which binds PtdIns(4,5)P2, display high affinity for phosphoinositides by 
forming specific contacts with lipid headgroups [14;15].  More recently, PH domains have 
been shown to serve as protein-protein interaction motifs, with binding of the PH domain of 
β-adrenergic kinase to heterotrimeric Gβγ-subunits, and various PH domains binding to Rho-
family GTPases [16-18]. 
ENTH and ANTH Domains 
 ENTH (epsin 1 N-terminal homology) and ANTH (AP180 N-terminal homology) 
domains are α-helical superhelical domains that preferentially bind PtdIns(4,5)P2 [19;20].  
4
 Proteins containing ENTH or ANTH domains are typically involved in clathrin and receptor 
mediated endocytosis, and because of additional protein recognition motifs are thought to 
serve as scaffold proteins and assemble protein complexes [21].  Structural studies detail 
specific interactions made between PtdIns(4,5)P2 and the ENTH domain of epsin, and 
between PtdIns(4,5)P2 and the ANTH domain of CALM [22;23].  Binding of PtdIns(4,5)P2 to 
solvent exposed residues within the ANTH domain of CALM contributes to the relatively 
weak observed affinity (Kd of ~5 µM) [22].  Alternatively, the ENTH domain of epsin forms 
a binding pocket for the inositol headgroup, and makes additional contacts with the glycerol 
backbone of PtdIns(4,5)P2, leading to a 10-fold higher affinity for PtdIns(4,5)P2 compared to 
ANTH domains [23].  Additionally, ENTH domains likely penetrate the lipid bilayer to 
stabilize the association of ENTH domain-containing proteins with membranes [24;25].   
1.3.2 Monophosphate PtdIns Binding Domains 
 Proteins containing PX (Phox homology) domains are typically involved in vesicular 
trafficking, protein sorting, and lipid modifications [26;27].  Although several 
phosphatidylinositol lipids (i.e. PtdIns(3)P, PtdIns(3,4)P2, and PtdIns(4,5)P2) interact with 
PX domains, PtdIns(3)P represents the major lipid binding partner for PX domains [27-29].  
Indeed, Yu et al. showed that all PX domains identified in Saccharomyces cerevisiae 
preferentially bind PtdIns(3)P [30].  Specificity of PX-domains for PtdIns(3)P is conferred 
through hydrogen bonding between the PX domain and free hydroxyl groups at the 4- and 5-
positions on inositol.  The presence of phosphate groups at the 4- and 5-positions would 
result in steric clashes between the inositol headgroup and the majority of PX domains.  The 
ability of PX domain-containing proteins to anchor to the membrane is aided by a membrane-
interaction loop, which penetrates the lipid bilayer.   
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  FYVE domains (Fab1p, YOTP, Vac1p, and EEA1), similar to PX domains, 
preferentially bind PtdIns(3)P, but with relatively weak affinities [31;32].  Proteins 
encompassing FYVE domains are involved in endocytosis, regulation of the actin 
cytoskeleton, and growth factor signaling [33].  Currently, 27 FYVE domain-containing 
proteins have been identified and typically have zinc finger-like structures, with additional 
residues coordinating lipid binding [34].  PtdIns(3)P binding is conferred within a shallow 
hydrophobic pocket, with hydrogen bonds formed between the free hydroxyl groups of the 
inositol ring and the side-chains of the binding motif [35].  As observed with other low 
affinity lipid binding domains, FYVE domains partially embed into the membrane to 
stabilize membrane localization [24].    
1.3.3 Other Phosphoinositide Binding Domains 
 Several other phosphoinositide binding domains have been identified, the majority of 
which are found in proteins involved in the regulation of the actin cytoskeleton.  For 
instance, PtdIns(4,5)P2 binding to WASP (Wiskott-Aldrich syndrome protein) enhances  
WASP-induced Arp2/3-mediated actin polymerization [36].  Additionally, the interaction of 
PtdIns(4,5)P2 with profilin or cofilin, two actin binding proteins, inhibits the ability of 
profilin and cofilin to bind actin monomers [37;38].  FERM domains (ezrin/radixin/moesin), 
similar in structure to PH domains, bind PtdIns(4,5)P2 and release a carboxy-terminal 
inhibitory domain allowing FERM-domain containing proteins to link actin filaments to the 
plasma membrane [39].  Finally, binding of PtdIns(4,5)P2 to the carboxy-terminal region of 
tubby sequesters the protein away from downstream nuclear effectors.  Upon hydrolysis of 
PtdIns(4,5)P2, tubby translocates to the nucleus, where it serves as transcription factor [40]. 
1.3.4 PtdIns(4,5)P2 and Disease 
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  Because of the considerable number of proteins involved in lipid signaling, 
phosphoinositide metabolism is potentially involved in the aetiology of several diseases.  
Lithium has historically been used to treat patients with bipolar disorder; however, the 
precise mechanism of lithium action is unknown.  One proposed mechanism entails the 
ability of lithium to inhibit inositol monophosphatases, thereby reducing the levels of inositol 
available for the de novo synthesis of phosphoinositides [41;42].  Additionally, several PI 
kinases map to chromosomal regions linked to bipolar disorder [43;44].  An increase in 
phospholipase activity has also been linked to cardiomyocyte apoptosis, possibly a 
consequence of decreased PtdIns(3,4,5)P3 formation, which alters the PKB (protein kinase b) 
survival pathway [45].  There has also been a correlation found between Lowe’s syndrome, 
which is characterize by severe mental retardation, and elevated PtdIns(4,5)P2 levels [46].  
Several other diseases have been linked to PtdIns(4,5)P2 metabolism; however, the 
importance of lipid levels and signaling pathways is not immediately available.  Because of 
the ability to regulate many signaling pathways at multiple different localizations within the 
cell, it would not be surprising to uncover significant correlations between phosphoinositide 
metabolism and human diseases.     
 1.4 Phosphoinositide-Specific Phospholipase C 
 The cellular action of a variety of extracellular signaling molecules, including 
hormones, neurotransmitters, and growth factors, is elicited through receptor-mediated 
stimulation of phosphoinositide-specific phospholipase C (PLC) enzymes.   In response to 
receptor activation, PLC enzymes recognize and hydrolyze the inositol headgroup of 
PtdIns(4,5)P2, generating two intracellular second messengers: diacylglycerol, which in turn 
activates PKC (protein kinase C), and inositol 1,4,5-trisphosphate, which mobilizes 
7
 intracellular calcium [47;48].  In addition to generating second messengers, activation of 
PLC enzymes terminates or promotes downstream signaling of proteins that employ 
phosphoinositide binding for membrane association and/or regulation of activity. 
 Hormonal regulation of phosphoinositide metabolism was first observed in the 1950s 
by Hokin and Hokin, who believed they were studying the incorporation of 32P into RNA.  
Instead, addition of carbamylcholine or acetylcholine to pigeon pancreatic slices resulted in 
the incorporation of 32P into the phospholipid fraction, a phenomenon later termed the “PI 
effect” [49].  A wealth of experiments, spearheaded by Michell, Berridge, and others, further 
implicated extracellular stimulation of receptors with phospholipid metabolism [50-52].  The 
Nishizuka group discovered the link between DAG formation and the activation of PKC in 
the late 1970s and early 1980s [53].  Experiments by Streb et al. showed an Ins(1,4,5)P3-
dependent link between receptor activation and increases in intracellular calcium [54].  These 
experiments, performed over the course of 40 years, laid the groundwork for researchers to 
dissect intricate signaling pathways integrated through PLC-mediated phosphoinositide 
metabolism. 
 By the early 1990s, Rhee and colleagues identified and cloned three subfamilies of 
PLC enzymes: PLC-β, PLC-γ, and PLC-δ [55;56].  Over the next decade, three additional 
PLC family members, PLC-ε, PLC-ζ, and PLC-η, were identified.  Several PLC subfamilies 
include multiple members, bringing the total number of active isoforms to fourteen.  PLC-L, 
a PLC-like protein, lacks critical conserved amino acids in the X-region rendering the protein 
catalytically inactive [57].  PLC enzymes are multidomain, soluble proteins ranging in 
molecular size from ~70 kDa for the smallest PLC-ζ isozyme, to 125-150 kDa for the PLC-β 
isozymes, and upwards of ~250 kDa for the largest isozyme, PLC-ε.  PLC enzymes are 
8
 conserved throughout evolution, with simple PLC-δ-like isoforms expressed in yeasts, slime 
molds, filamentous fungi, and plants [58].  As cellular signaling components began to 
diversify, so to did PLC enzymes, leading to the appearance of the more complex PLC 
subfamilies.  Although PLC subfamilies arise from varying sequence conservation and 
elaborate regulatory domains, all PLC isoforms share a conserved catalytic region for the 
recognition and hydrolysis the inositol headgroup from phosphoinositide lipids.   
1.4.1 Catalytic Function and Structure of Conserved PLC Domains 
 Collectively, PLC enzymes are calcium-dependent phosphodiesterases that hydrolyze 
PtdIns(4,5)P2 to form DAG and Ins(1,4,5)P3.  Although the six subfamilies of PLC enzymes 
are highly variable, several domains comprising the catalytic region are conserved in all PLC 
isoforms.  Moving sequentially from the amino- to the carboxy-terminal regions of the 
enzymes, all PLC isozymes contain a PH domain (excluding PLC-ζ), EF-hand repeats, 
catalytic X- and Y-boxes, and a C2 domain (Figure 1.2).  Individual PLC subfamilies arise 
from elaboration of the conserved regions with additional protein binding and/or modular 
domains. 
Catalytic X and Y Box 
 The X- and Y-boxes are the most highly conserved regions, with 60-70% amino acid 
identity among families, with higher conservation found within subfamilies.  The X- and Y-
boxes fold together with alternating α-helices and β-strands to form a catalytic triose 
phosphate isomerase-like (TIM) barrel [59].  A three-dimensional crystal structure of the 
catalytic core (EF-hand through C2 domains) of PLC-δ1 bound to Ins(1,4,5)P3 revealed the 
organization of the catalytic regions of PLC-δ as well as the potential mechanism of  
PtdIns(4,5)P2 catalysis [60].  The crystal structure of PLC-δ also revealed a hydrophobic 
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 ridge surrounding the active site believed to penetrate the lipid bilayer [61], increasing 
catalytic activity by allowing maximum access of the catalytic site to membrane-associated 
phosphoinositide substrate [62;63]. 
 The reaction performed by PLC enzymes results in the cleavage of the oxygen-
phosphorus bond connecting DAG to the 1-position of the inositol ring (Figure 1.1).  The 
initial step in hydrolysis is the recognition of phosphoinositide substrate by the catalytic TIM 
barrel.  Although eukaryotic PLC enzymes hydrolyze several phosphoinositide substrates, the 
rank order of specificity is PtdIns(4,5)P2 > PtdIns(4)P > PtdIns [64;65].  Structure 
determination of PLC-δ suggests several amino acids within the catalytic region of PLC are 
involved in forming hydrogen bonds and salt-bridges between lipid substrate and PLC 
enzymes.  Interactions between Lys-438, Lys-440, Ser-522, and Arg-549 of PLC-δ with the 
4- and 5-phosphorylated positions of the inositol ring form phosphomonoesters [66].  The 
inositol ring also participates in catalysis, as the 2-hydroxyl group is necessary for the 
nucleophilic attack on the di-ester phosphate bond, thereby generating the cyclic 
intermediate. 
    Several amino acids involved in hydrolysis of PtdIns(4,5)P2 are conserved between 
all PLC subfamilies, including amino acids His-311, His-356, Glu-341, Asp-343, and Glu-
390 of PLC-δ [67].  The coordination of a calcium ion within the active site of PLC enzymes 
is also required for catalytic activity.  In the structure of PLC-δ, a calcium ion is coordinated 
by the sidechains of Asn-312, Glu-341, Aps-343, and Glu-390, and also forms hydrogen 
bonds with the 2-hydroxyl group of inositol [66].  Utilizing structural information provided 
by PLC-δ in complex with various phosphorylated species of inositol headgroups, Ellis et al. 
proposed a three step catalytic mechanism for the hydrolysis of PtdIns(4,5)P2 [60].  The first 
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 step involves the formation of a 1,2-cyclic inositol phosphate intermediate resulting from the 
protonation of the DAG leaving group and the in-line nucleophilic attack of the 2-hydroxyl 
group of inositol.  During this step, the calcium ion participates in the formation of the cyclic 
intermediate by lowering the pKa of the attacking hydroxyl and neutralizing the negative 
charge generated during the transition state.  Following formation of the cyclic intermediate, 
His-356 utilizes a proton from a water molecule to attack the cyclic intermediate and 
complete the hydrolysis of PtdIns(4,5)P2.  The final step in PtdIns(4,5)P2 hydrolysis is the 
release of soluble inositol phosphate products.  Mutation of His-311 and His-356, as well as 
the amino acids involved in the coordination of the calcium ion, confirmed the requirement 
of these residues as the catalytic activity of PLC-δ was reduced or destroyed upon mutation 
[68;69].  
X-Y Linker Region 
 The amino acid sequence linking the X- and Y-catalytic regions is highly variable in 
both length and sequence among PLC subfamilies.  Several studies suggest the linker regions 
of PLC isozymes provide a mechanism of autoinhibition through occlusion of the active site.  
Limited proteolysis of the X-Y linker region of PLC-β2 increased basal activity of the 
enzyme 30-fold relative to uncleaved enzyme [70].  Structural analysis confirmed occlusion 
of the PLC-β2 active site by the X-Y linker region [71].  Similar proteolysis experiments 
with PLC-δ1 also resulted in increase basal activity, suggesting the X-Y linker provides a 
general mechanism of autoinhibition for other PLC isozymes [60].  Finally, replacement of 
the X-Y linker region of PLC isozymes with a short flexible linker sequence results in a 
dramatic increase in basal enzyme activity (S. Hicks, T.K. Harden, J. Sondek, unpublished 
data).  Enzyme activity was quantified after transient expression in COS-7 cells of PLC-β2, 
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 PLC-ε, and PLC-δ1 lacking the X-Y linker regions compared or wild type enzymes.  
Furthermore, when reconstituted in phospholipid vesicles, purified PLC-β2 lacking the X-Y 
linker region also exhibits 5-10 fold higher activity than PLC-β2.  Transfection experiments 
suggested that PLC-β and PLC-ε lacking the full X-Y linker retained regulation by Rac1 or 
Gβγ, or RhoA or Ras, respectively.  The mechanism by which the X-Y linker region is 
released from the active site is unknown.  However, proteins shown to regulate PLC 
isozymes, such as Gβγ regulation of PLC-β, or RhoA regulation of PLC-ε, may interact with 
the X-Y linker region causing release of the X-Y linker from the active site.  Alternatively, 
interfacial activation by repelling the negatively charged linker from the negatively charged 
membrane is more likely in the activation of PLC-β2 by Rac, which results in no 
conformational change within the catalytic regions of PLC-β2. 
PH Domains 
 With the exception of PLC-ζ, and certain splice variants of PLC-β4, all PLC isozymes 
have a PH domain preceding the EF-hand repeats and catalytic TIM barrel.  As discussed 
previously, PH domains typically aid in membrane association by recognizing and binding 
negatively charged lipids.  Indeed, the PH domain of PLC-δ1 binds with high affinity to 
PtdIns(4,5)P2, which is required for enzyme activity, presumably serving as a tether bringing 
the catalytic TIM barrel to the membrane associated substrate [14;72;73].  Alternatively, 
PLC-γ specifically binds PtdIns(3,4,5)P3 with high affinity, resulting in translocation to the 
plasma membrane [74].  The PH domains of PLC-β isozymes do not preferentially bind 
phosphoinositides and are not required for enzyme activity [75].  Interestingly, the PH 
domains of PLC-β isozymes are involved in protein-protein interactions with heterotrimeric 
Gβγ-subunits and/or the small GTPase Rac1 (see section 1.4.2).  The PH domains of PLC 
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 isozymes, though variable in sequence and binding specificity, appear to serve a common 
function in assisting membrane association of PLC enzymes. 
EF-Hand Repeats 
 Included within all PLC isoforms, EF-hand repeats are helix-loop-helix structures 
divided into pairwise lobes [61].  EF-hand repeats, also found in calmodulin and tropinin, 
typically serve as calcium binding motifs, with each repeat binding to one calcium ion; 
however, naturally occurring variants have been identified that lack calcium binding [76].  
The role of EF-hand repeats in the context of PLC enzymes is unclear.  The crystal structure 
of PLC-δ1 suggests an absence of calcium binding to the EF-hand repeats.  However, other 
studies have shown that calcium binding is necessary for the interaction of the EF-hand 
domain of PLC-δ1 with PtdIns(4,5)P2 [77].  Indeed, deletion of this region of PLC-δ1, or 
mutation of requisite calcium-binding amino acids, results in the loss of enzyme activity [78].  
These data suggest an essential role for the EF-hand repeats in modulating PLC-δ1 enzymatic 
activity.  In contrast, although PLC-β and PLC-γ isozymes contain the four helix-loop-helix 
repeats, the domains lack residues required for metal binding.  EF-hand repeats potentially 
serve as a flexible linker between the PH domains and catalytic regions of PLC isozymes that 
do not require EF-hand repeats for catalytic activity.     
C2 Domains   
 Typically about 120 amino acids in length, C2 domains are found in a variety of 
membrane-associated proteins.  The general structure of C2 domains is an eight β-stranded 
antiparallel sandwich, with three loops at one edge of sandwich forming calcium binding 
sites [79].  Several C2 domains bind calcium to mediate the association of C2 domains with 
phospholipids.  The C2 of PLC-δ1 employs calcium binding to mediate a ternary complex 
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 between the enzyme, a calcium ion, and phosphatidylserine [80].  Under specific in vitro 
conditions, phosphatidylserine binding to the C2 domain of PLC-δ1 increased the functional 
activity of the enzyme.  The calcium-binding regions of PLC-δ1 are well conserved among 
species, suggesting the C2 domain plays an important regulatory role for PLC-δ isozymes.  
PLC-β and PLC-γ isozymes lack critical residues required for calcium binding, suggesting an 
alternate role for the C2 domain not involving calcium-mediated phospholipid interactions.  
The C2 domain of PLC-β1 has been shown to assist in the association of Gαq to the carboxy-
terminal extension of the enzyme [81].  Due to the absence of a PH domain, PLC-ζ may 
utilize binding of PtdIns(3)P via the C2 domain for membrane association [82].  The 
regulatory role of C2 domains in the context of the remaining PLC isoforms is unknown, 
though evidence regarding PLC-δ and PLC-β suggest C2 domains are potential lipid or 
protein binding regulatory domains.   
1.4.2  Phospholipase C Subfamilies and Regulation 
Phospholipase C-δ 
 Mammalian PLC-δ isoforms are archetypical PLC enzymes evolutionary conserved 
in primitive eukaryotes, including yeast, slime molds, and plant PLC [83-85].  The PLC-δ 
isoforms are among the simplest PLCs, containing only the conserved PH domain, EF-hand 
repeats, X- and Y-boxes, and carboxy-terminal C2 domain.  There are three mammalian 
family members, PLC-δ1, δ3, and δ4, sharing approximately 50% homology.  PLC-δ2 was 
originally identified from a bovine brain library; however, further analysis revealed PLC-δ2 
was the homologue of human/mouse PLC-δ4 [86].  PLC-δ1 is the most widely expressed 
PLC-δ isoform, with highest expression in brain, heart, lung, skeletal muscle, and testis 
(Table 1.1) [55].  Expression of PLC-δ1 is elevated in the brains of patients with Alzheimer’s 
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 disease compared to non-affected individuals but the role of PLC-δ1 in the brain and/or 
disease is unknown [87].  PLC-δ3 and PLC-δ4 have similar expression patterns, with both 
isotypes found in brain, skeletal muscle, and heart [88-90]. 
 The solved crystal structures of the PH domain of PLC-δ1 in complex with 
Ins(1,4,5)P3, and the catalytic EF-C2 region of PLC-δ1, provided the first structural 
information for the conserved regions found in all PLC isozymes [61;91].   As discussed 
above, these structures provided insight into the potential regulation of PLC-δ1 through the 
binding of PtdIns(4,5)P2 to the PH domain, and the calcium-dependent binding of PS to the 
C2 domain.  In response to these observations, Mark Lemmon proposed a “tether and fix” 
mode of PLC-δ regulation [92].  The proposed mechanism involves “tethering” of PLC-δ to 
the membrane via association with PtdIns(4,5)P2, with subsequent PS binding to the C2 
domain “fixing” the enzyme in a proper orientation to expose the active site to PtdIns(4,5)P2 
substrate.  Accumulation of soluble Ins(1,4,5)P3 would serve as a negative regulator or PLC-
δ activity by competing with PtdIns(4,5)P2 for binding to the PH domain.  Another theory of 
PLC regulation, similar to the “tether and fix” model, is the concept of “membrane scooting” 
originally described by Hershberg and de Hass in 1976 in context of phospholipase A2 
regulation [93].  Membrane scooting is a process that involves two successive equilibria, the 
first of which is the interfacial association of a water-souble enzyme to the membrane, and 
the subsequent interaction between a single enzyme molecule and a single substrate 
molecule.  In the context of PLC-δ isozymes, the preferential binding of PtdIns(4,5)P2 to the 
PH domain would anchor the enzyme to the lipid bilayer allowing the processive hydrolysis 
of substrate. 
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  PLC-δ is one of the more calcium-sensitive PLC isoforms, potentially the result of 
calcium-dependent binding of both PtdIns(4,5)P2 to the PH domain, and PS binding to the C2 
domain [77;80].  One hypothesis suggests PLC-δ isoforms are activated as a secondary 
response to receptor-regulated PLC isoforms, such as PLC-β or PLC-γ [94].  The increase in 
intracellular calcium resulting from PLC-β or PLC-γ activation would promote the calcium-
dependent translocation of PLC-δ isoforms to the plasma membrane, resulting in a prolonged 
PLC-dependent calcium signal.  Finally, evidence suggests PLC-δ is potentially regulated by 
a novel class of G-protein, Gh.  Association of PLC-δ with GDP-bound Gh has been 
proposed to negatively regulate PLC-δ activity, whereby receptor activation and GTP 
binding to Gh, PLC-δ is liberated, allowing the enzyme to actively hydrolyze substrate [95].     
Phospholipase C-β 
 PLC-β isozymes contain a unique carboxy-terminal extension of approximately 400 
amino acids following the C2 domain (Figure 1.2).  The four PLC-β isozymes, PLC-β1-4, 
have unique tissue distributions and phenotypic traits among knockout mice.  PLC-β1 is most 
widely expressed in the brain, and PLC-β1-/- mice develop epileptic seizures, often leading to 
sudden death [65].  In mice lacking the hematopoietic cell specific PLC-β2, chemokine 
signaling is disrupted.  However, chemotaxis of hematopoeitic cells from PLC-β2 knockout 
mice is not altered [96].  PLC-β3 is expressed in several tissues including the liver, parotid 
gland, and low levels in the brain, and mice lacking PLC-β3 display decreased sensitivity to 
µ-opioid signaling [97].  Finally, mice lacking PLC-β4, found specifically in the cerebellum 
and retina, display ataxia, caused by loss of metabotropic glutamate-receptor signaling, and 
defective visual responses [65;98].  The presence of individual PLC-β isoforms in distinct 
tissues suggests a non-redundant role for the individual PLC-β isoforms.    
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  Prior to the known involvement of heterotrimeric G proteins in PLC-dependent 
calcium signaling, several experiments suggested a pertussis toxin (PTX)-dependent and 
PTX-independent component of phosphoinositide signaling [99;100].  The PTX-independent 
regulation of PLC involves binding of the carboxy-terminal extension of PLC-β to the GTP-
bound heterotrimeric Gα-subunit, Gαq [101-103].  Although all PLC-β isoforms are activated 
by direct association with Gαq, PLC-β1 and PLC-β3 are the most sensitive to Gαq regulation 
[101;102].  PTX-sensitive regulation of PLC-β isoforms is mediated through association with 
heterotrimeric Gβγ subunits originating from Gαi-dependent signals [104-106].  Deletion of 
the carboxy-terminal extension of PLC-β does not inhibit Gβγ-dependent activation of PLC-
β, suggesting Gαq and Gβγ utilize independent regions of interaction with PLC-β to regulate 
enzyme activity [107].  Indeed, the region of Gβγ interaction appears to be the PH domain of 
PLC-β, and possibly another site within the Y-region of the catalytic domain [81].  PLC-β2 
and PLC-β3 are the most sensitive to Gβγ regulation, while PLC-β1 is weakly activated, and 
PLC-β4 is insensitive to Gβγ activation [104;105;108].  This classical view of PLC-β 
regulation via interactions with various heterotrimeric G proteins positions PLC-β 
downstream of innumerable hepthahelical receptors coupled to various G proteins. 
 The complexity of PLC-β signaling, and PLC signaling in general, increased 
dramatically in 1997 when Illenberger and colleagues reported the direct, GTP-dependent 
activation of PLC-β2 by Rho family GTPases, specifically Rac1 and Cdc42 [109].  PLC-β2 
demonstrated the highest sensitivity to Rac activation, while PLC-β3 showed little effect, and 
PLC-β1 was completely insensitive.  Subsequent studies by Snyder et al. verified Rac-
regulated PLC-β2 activity by coexpressing PLC-β2 with constitutively active mutants of 
Rac1, Rac2, and Rac3 in COS-7 cells and measuring inositol phosphate accumulation [17].  
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 Additionally, a chimera of PLC-β2 containing the PH domain of PLC-β1 resulted in a loss of 
Rac-regulated enzyme activity, suggesting Rac interacts specifically with the PH domain of 
PLC-β2.  [110].  Surface plasmon resonance experiments showed the isolated PH domain of 
PLC-β2 specifically bound activated Rac GTPases, verifying the Rac binding site within 
PLC-β2 [17].  
 Jezyk and coworkers ultimately defined the interaction between PLC-β2 and Rac1 by 
solving the first crystal structure of a PLC enzyme in complex with a protein activator [71].  
The structure of a fragment of PLC-β2 spanning the PH to C2 domains in complex with 
activated Rac1 confirmed the specific interaction of Rac1 with the PH domain of PLC-β2.  
The switch regions of Rac1 clamp down on a hydrophobic ridge within the PH domain, 
suggesting the interaction is physiologically relevant as G proteins engage known effectors 
through interactions with the switch regions.  Although binding to Rac1 in cells would result 
in translocation of PLC-β2 to the plasma membrane, the crystal structure also revealed that 
binding to Rac1 would align PLC-β2 in a favorable orientation to facilitate access of the 
catalytic TIM barrel to phosphoinositide substrate.  Interestingly, the residues of Rac1 that 
interact with PLC-β2 share substantial identity with other Rho family GTPases, specifically 
RhoA and Cdc42.  Whereas the electrostatic potential of Rac and the PH domain of PLC-β2 
are favorable for complex formation, the electronegative potential of RhoA would repel the 
like-charged PH domain of PLC-β2.  Cdc42 has a similar surface charge potential as Rac1, 
and although Cdc42 has been shown to increase PLC-β activity in vitro, a Phe56 in Cdc42, 
compared to Trp56 in Rac1, creates an unfavorable situation for complex formation between 
Cdc42 and the PH domain of PLC-β2.   
Phospholipase C-γ 
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  Two PLC-γ isozymes have been identified; the ubiquitously expressed PLC-γ1, and 
the hematopoietic cell enriched PLC-γ2 (Table 1.1) [55].  The activation of various growth 
factor receptors, including the receptors for platelet-derived growth factor (PDGF), epidermal 
growth factor (EGF), and nerve growth factor (NGF) leads to the activation of PLC-γ 
isozymes [111-113].  PLC-γ isoforms are characterized by unique X-Y linker regions, which 
contain a split PH domain, two SH2 domains, and an SH3 domain (Figure 1.2).  
Phosphorylated residues on tyrosine kinase receptors serve as high affinity binding sites for 
SH2 domains within the X-Y linker of PLC-γ, allowing recruitment of the enzyme to the 
plasma membrane, and phosphorylation of the enzyme at two residues within the linker 
region, specifically, Tyr771 and Tyr783 [114].  While phosphorylation of these residues is 
necessary for PLC-γ activity, neither is sufficient to activate the enzyme.  Other studies 
suggest activation of certain growth factor receptors stimulate PI 3-K to form 
PtdIns(3,4,5)P3, which in turn binds the PH domain and carboxy-terminal SH2 domain of 
PLC-γ, anchoring the enzyme to the membrane.  One potential hypothesis is that 
phosphorylation of PLC-γ releases autoinhibition of the X-Y-linker, while binding to 
PtdIns(3,4,5)P3 confers membrane association and enzyme activity. 
 Several other mechanisms of PLC-γ activation have been identified including 
phosphorylation by non-receptor tyrosine kinases, activation of immunoglobin receptors, and 
stimulation of GPCRs [76;115].  Most recently, PLC-γ2, but not PLC-γ1, has been identified 
as a direct downstream effector of Rac GTPases through a mechanism not involving tyrosine 
kinase phosphorylation or PtdIns(3,4,5)P3 generation [116].  While several mechanisms of 
PLC-γ regulation have been observed, the specific biological function of these isozymes 
remains unclear.   To varying degrees, PLC-γ1 has been associated with several cellular 
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 processes including cell cycle control, transformation, control of the actin cytoskeleton, and 
development [115].  Indeed, PLC-γ1 deficient mice do not survive past embryonic day nine, 
suggesting an essential role for PLC-γ1 in development [117].  Knockout of PLC-γ2 is not 
embryonic lethal; however, these mice exhibit defective immunoglobin receptor signaling 
and reduced numbers of mature B cells [118].   
Phospholipase C-ζ   
 Following fertilization of mammalian eggs, a series of Ins(1,4,5)P3-dependent 
calcium oscillations occur.  Several experiments determined that a soluble factor released by 
sperm is responsible for inducing calcium oscillations in fertilized eggs.  Subsequent studies 
ruled out the involvement of known PLC isoforms, lending support to the hypothesis that an 
undiscovered PLC isoform released by sperm triggers calcium oscillations.  In 2002, 
Saunders et al. identified the novel, sperm specific, PLC-ζ sequence by examining short 
EST-sequences isolated from mouse and human testis [119].  PLC-ζ is approximately 70 kDa 
and conserved in at least 8 mammalian species, as well as chickens.  Sharing the most 
homology with PLC-δ, PLC-ζ lacks regulatory domains found in other PLC isoforms, and is 
the only mammalian PLC isoform devoid of a PH domain.  The enzyme retains the core 
catalytic X- and Y-boxes, as well as four EF-hand repeats and a C2 domain (Figure 1.2). 
 The mechanism of PLC-ζ regulation in a cellular environment has yet to be fully 
ascertained.  Calcium binding to the EF-hand repeats potentially regulates functional PLC 
activity, as removal of the first two EF-hands results in a rightward shift of the EC50 for 
calcium and decreases enzyme activity [82].  Interestingly, PLC-ζ is sensitive to calcium 
concentrations found in typical resting cells (~100 nM), suggesting calcium levels in 
fertilized eggs potentially regulates the activity of PLC-ζ, but not other PLC isoforms present 
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 in fertilized eggs.  The C2 domain of PLC-ζ does not appear to bind calcium; however, 
calcium-independent binding of PtdIns(3)P to the isolated C2 domain has been observed 
[82].  C2 domain-mediated membrane association of PLC-ζ may be integral to enzyme 
regulation as PLC-ζ lacks a PH domain, which is utilized by several PLC isozymes for 
membrane localization.  Finally, a nuclear localization signal (NLS) within the X-Y linker 
region of PLC-ζ may play a vital role in the regulation of enzyme activity [120].  
Fluorescently tagged-PLC-ζ was visualized in cells and shown to alternate between a 
perinuclear region during interphase when calcium oscillations are absent, to a cytoplasmic 
localization corresponding to increased calcium oscillations and mitosis [120].       
Phospholipase C-η 
 In 2005, four groups independently identified the newest PLC isoform, PLC-η, using 
data mining of EST databases and nucleotide sequences [121-124].  Two family members 
were identified, which mapped to different chromosomes in humans and mice: the shorter, 
115 kDa PLC-η1, and the longer, 125 kDa PLC-η2.  These isozymes share ~50% homology 
and both contain the canonical PH domain, EF-hand repeats, catalytic TIM barrel, and C2 
domain (Figure 1.2).  Following the catalytic region is a long carboxy-terminal Ser/Pro-rich 
sequence terminating in a PDZ-binding motif.  PLC-η1 and PLC-η2 are brain specific 
enzymes, with enriched expression found in hippocampus, cerebral cortex, Purkinje cells, 
and olfactory bulb [122].  The regulation of PLC-η isozymes has yet to be determined in 
detail, though evidence suggests higher calcium sensitivity compared to other PLC isoforms, 
such as PLC-β [121].  Experiments by Zhou et al. indicate increased phosphoinositide 
accumulation in COS-7 cells transiently transfected with heterotrimeric Gβγ subunits and 
PLC-η, potentially positioning PLC-η downstream of GPCR activation [123].  Unpublished 
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 in vitro experiments confirm direct regulation of PLC-η by Gβ1γ2 as determined by 
reconstitution of purified proteins in phospholipid vesicles (E. Zhou and T.K. Harden.). 
Phospholipase C-ε 
 The final PLC isozyme subfamily, PLC-ε, will be discussed in detail in the following 
section. 
1.5 Phospholipase C-ε 
1.5.1 Identification and Cloning 
 In 1986, two groups, Cantley and coworkers, and Wakelam et al., independently 
suggested a role for Ras family proteins in the regulation of phosphoinositide metabolism 
[125;126].  Nearly twelve years later, while searching for proteins that interact with the 
nematode Caenorhabditis elegans homologue of Ras (LET-6012V), Kataoka and coworkers 
isolated a novel PLC isoform [127].  The 210 kDa sequence possessed the conserved 
catalytic X- and Y-regions typified by all PLC isoforms and included the residues required 
for catalytic phosphodiesterase activity.  Additionally, PLC210, the largest PLC isoform, 
contains novel regulatory domains not found in other PLC isoforms.  PLC210 was the first 
PLC isoform identified encompassing known Ras-associating domains, including an amino-
terminal CDC25 (cell division cycle protein 25-like domain) RasGEF domain, and tandem 
carboxy-terminal RA (Ras-associating) domains.  The predicted Ras interacting domains 
suggests PLC210 is a bifunctional enzyme, acting downstream of activated Ras through the 
RA domains, and as an activator of Ras GTPases, potentially leading to an auto-feedback 
mechanism. 
 Following identification of the C. elegans PLC210 gene, three groups independently 
utilized the sequence information to clone PLC-ε, the mammalian homologue of PLC210.  
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 Song et al. and Lopez et al. identified two human splice variants of PLC-ε differing in the 
amino-terminal region, yielding sequences of 1994 and 2303 amino acids, respectively 
[128;129]. Northern blot analysis with human mRNA revealed highest PLC-ε expression in 
heart, with lower expression levels in lung, kidneys, and brain [129].  Simultaneously, a 
single, 2281 amino acid rat ortholog of PLC-ε was cloned and shown to have functional 
phospholipase activity both in vivo and in vitro [130].  The mammalian homologues contain 
a similar domain organization as PLC210, including the carboxy-terminal RA domains and 
CDC25 domain; however, these groups did not identify a PH domain or EF-hand repeats.  A 
more extensive scanning of the mammalian PLC-ε sequence by Wing et al. confirmed the 
presence of a PH domain, as well as EF-hand repeats [131].  Identification of the additional 
domains provided a complete domain architecture for PLC-ε, which includes, moving from 
the amino- to the carboxy-terminus, a Cys rich region, CDC25 domain, PH domain, EF-hand 
repeats, catalytic X- and Y-boxes, C2 domain, and tandem RA domains. 
1.5.2 Unique Structural and Regulatory Domains 
RA Domains 
 RA (RalGDP/AF6 or Ras-associating) domains are approximately 100 amino acid 
ubiquitin-like protein folds originally defined by Ponting and Benjamin [132].  Although 
over 100 RA domains have been identified, only a subset of RA domain-containing proteins 
are authentic Ras-family effectors.  Sequence homology among RA domains is generally low 
and RA domains are characterized by conserved secondary structural elements.  Two regions 
within the carboxy-terminal region of the C. elegans protein PLC210 share predicted 
secondary sequence homology with previously confirmed RA domains, including RalGDS 
and AF-6.  Utilizing purified RA domain constructs of PLC210 (RA1 and RA2), Shibatohge 
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 et al. showed direct association of GTP-bound H-Ras with the RA1 domain.  However, 
binding of H-Ras to the RA2 domain was not observed [127].  Mutations within the switch 
regions of H-Ras caused a loss of interaction with PLC210 as observed in a two-hybrid 
system, further implicating the RA1 domain as an authentic Ras-binding domain. 
 Cloning of mammalian PLC-ε homologs also revealed the presence of tandem 
carboxy-terminal RA domains.  In contrast to the observed interaction between the RA1 
domain and Ras GTPases in C. elegans, it is the RA2 domain of mammalian PLC-ε isoforms 
that interact with Ras GTPases [130].  Studies by Song et al. show a direct, GTP-dependent 
association of H-Ras and Rap1a with a fragment of human PLC-ε encompassing both RA1 
and RA2 domains [128;133].  Additional two-hybrid analysis suggested RA domain 
specificity, as other GTPases, such as Rho GTPases, RalA, and R-Ras, did not interact with 
the RA domains.  A sequence alignment of the RA2 domain of PLC-ε with several RA 
domains from other Ras effectors revealed several critical amino acids required for Ras 
binding [130].  Two lysine residues (K2150 and K2152) in the second RA domain of rat 
PLC-ε were mutated to either alanine or glutamic acid.  Mutation of Lys2150 to alanine or 
glutamic acid reduced in vitro H-Ras binding by 59% and >99%, respectively.  Mutation of 
Lys2152 was not as significant as Lys2150; however, a charge reversal of both Lys2150 and 
Lys2152 to glutamic acid reduced H-Ras binding by 97% of wild-type binding.  
Additionally, mutations within the Ras effector regions were tested for binding to the RA 
domains of PLC-ε.  The RA2 domain of PLC-ε retained the ability to bind H-Ras E37G and 
H-Ras D38N, with less binding observed with H-Ras T35S and H-Ras Y40C.  Taken 
together, these experiments suggest PLC-ε is an authentic H-Ras effector, utilizing 
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 interactions with switch regions of GTP-bound H-Ras for specific contacts within the RA 
domains of PLC-ε [130].   
Biochemical analysis of a variety of RA domains from various proteins, including 
those from PLC-ε, confirmed binding of H-Ras and Rap1B to the RA2 domain of PLC-ε.  
Isothermal titration calorimetry experiments derived affinities of 0.82 and 8.4 µM for H-Ras 
and Rap1B binding to the RA2 domain of PLC-ε, respectively [134]. Similar experiments 
with the RA1 domain of PLC-ε showed no significant affinity for H-Ras or Rap1B.  
Subsequently, NMR structures of the individual RA domains and the crystal structure of RA2 
in complex with activated H-Ras were solved [135].  Contacts made between the RA2 
domain and H-Ras are unique among Ras effectors, sharing contacts previously observed 
only between H-Ras and PI 3-Kγ [136].  In particular, while most effectors make contacts 
only with residues in switch I region of H-Ras, PLC-ε and PI 3-Kγ contact residues within 
switch I and II regions of H-Ras.  Structural comparison between the RA domains of PLC-ε 
reveals several negatively charged residues within the potential H-Ras binding region of the 
RA1 domain of PLC-ε.  The presence of these negatively charged residues creates an 
unfavorable surface for H-Ras binding due to the negatively charged surface potential of the 
switch regions of H-Ras.  Finally, the lower affinity of Rap GTPases for the RA2 domain can 
be partially explained by a charge reversal of Glu31 in H-Ras to a positively charged lysine 
in Rap GTPases, which would disrupt favorable charge interactions with the RA2 domain 
[135].   
While the understanding of PLC-ε RA domain interactions suggests regulation of the 
PLC-ε by various Ras family proteins, the function of tandem RA domains remains a 
mystery.  AF-6 is the only other Ras-family effector known to display tandem RA domains, 
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 and similar to PLC-ε, only one of the RA domains serves as a binding partner for Ras (note: 
several proteins have tandem RBDs) [137].  Structural analysis of the RA domains suggests 
that they are loosely tethered by a flexible linker and exist as independent entities.  The 
presence of tandem RA domains may be the result of genetic duplication during the evolution 
of PLC-ε.  This is an interesting proposition considering the RA1 domain of PLC210 seems 
to confer Ras binding, while mammalian PLC-ε binds Ras only through the RA2 domain.  
The functional significance of the RA1 domain is unclear but could potentially aid in protein 
stability, serve as a structural spacer sequence allowing PLC-ε to bind Ras proteins 
independent of enzyme activation, or have some yet undefined binding partners.   
CDC25 Domain 
 The amino-terminal region of PLC-ε shares a region of homology with the catalytic 
CDC25 domain of various RasGEF proteins [138].  Ras-family GEFs link activated 
membrane receptors to Ras activation by catalyzing the exchange of GDP for GTP on Ras 
family proteins, resulting in downstream activation of Ras-dependent signaling pathways.  
Approximately twenty mammalian Ras-family GEFs have been identified and characterized, 
and although CDC25 domains are specific for Ras-family proteins, individual RasGEFs 
confer specificity for particular Ras-family members [138].  Lopez et al. observed that 
overexpression of PLC-ε in TSA201 cells increased GTP-bound H-Ras quantified by co-
precipitation with GST-tagged Ras binding domain [129].  Increased levels of activated H-
Ras were not due to increased phospholipase activity, as a mutation that inhibits the catalytic 
activity of PLC-ε (H1144L) retained ability to increase GTP-bound H-Ras.  Furthermore, 
overexpression of full-length PLC-ε, or an amino-terminal construct containing the CDC25 
region increased the phosphorylation of MAP kinase, a Ras-dependent pathway.   
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 In contrast to the conclusions of Lopez et al.,  Jin et al. suggested that the CDC25 
domain of PLC-ε catalyzes nucleotide exchange on Rap1A, but displays no specificity for 
classical Ras GTPases, such as H-, K-, or N-Ras [139].  Purified PLC-ε constructs containing 
the CDC25 domain increased the rate of GDP release from Rap1A, but a construct lacking 
the CDC25 domain showed no GEF activity.  Overexpression of the same constructs in COS-
7 cells increased the levels of GTP-bound Rap1A and activated B-Raf, a downstream 
Rap1A-dependent kinase.  Additionally, epidermal growth factor stimulation of cells 
overexpressing Rap1A resulted in a sustained translocation of PLC-ε to perinuclear 
compartments of the cell, whereas PLC-ε lacking the CDC25 domain only transiently located 
to the same compartment.  The different observations made between the two groups may be 
attributed to the use of different PLC-ε splice variants and further experiments examining the 
specificity of the CDC25 domain would potentially resolve conflicting results. Likewise, the 
physiological consequence of RasGEF activity conferred by PLC-ε is unknown and requires 
further characterization. 
1.5.3 Regulation 
Ras Family GTPases 
 The identification and characterization of the RA domains of PLC-ε, as well as the 
ability to bind Ras GTPases in vitro, suggests the potential regulation of PLC-ε by various 
Ras family proteins.  Several groups have reported increased PLC-ε activity in cells 
overexpressing PLC-ε with various Ras family GTPases.  In addition to classical Ras 
proteins (H-, K-, and N-Ras), Rap1A, Rap2A, Rap2B, TC21, R-Ras, and Ral have all been 
reported to increase inositol phosphate accumulation in PLC-ε-dependent manner [140].  
Additionally, mutations within the RA2 domain of PLC-ε, or point mutations within the 
27
 switch regions of H-Ras, decrease Ras-dependent regulation of PLC-ε similar to the 
decreased binding observed by Kelley and colleagues (see section 1.5.2).  Reconstitution of 
purified PLC-ε with lipidated Ras GTPases in phospholipid vesicles has produced conflicting 
results regarding the direct activation of PLC-ε by Ras GTPases.  Song et al. and Bunney et 
al. observed increased PLC-ε activity in reconstituted lipid vesicles when presented with a 
single concentration of GTP-bound H-Ras or K-Ras, respectively [128;141].  Alternatively, 
experiments by Kelley and colleagues suggested H-Ras does not directly regulate PLC-ε 
activity in a similar assay system [130]. 
  Taken together, in vitro binding experiments and in vivo transfection data suggests 
PLC-ε enzyme activity is directly regulated by association with Ras GTPases.  However, the 
mechanism of Ras-dependent PLC-ε activation is unknown.  Ras GTPases, similar to other G 
proteins, are post-translationally modified by covalent attachment of lipid moieties, resulting 
in membrane localization of Ras proteins.  Binding of PLC-ε to activated Ras GTPases could 
therefore result in the translocation of PLC-ε to various plasma membranes leading to 
increased activity due to closer proximity to PtdIns(4,5)P2 substrate.  This hypothesis is 
supported by experiments coexpressing PLC-ε and H-Ras resulting in translocation of PLC-ε 
from the cytoplasm to the plasma membrane [133].  Another hypothesis involves 
conformational changes within PLC-ε in response to Ras binding to the RA domains causing 
a favorable conformation for lipid recognition and hydrolysis.  Finally, Bunney and 
colleagues hypothesize that the RA domains of PLC-ε autoinihibit enzyme activity by 
forming a complex with the catalytic region of the enzyme, which is disrupted upon binding 
of Ras and translocation to the plasma membrane [141]. 
Heterotrimeric G Proteins 
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  Cotransfection of TSA201 cells with mammalian PLC-ε in combination with various 
heterotrimeric Gα-subunits identified Gα12 as a regulator of PLC-ε-dependent inositol 
phosphate accumulation [129].  Although initial experiments by Lopez et al. showed no 
apparent Gα13-dependent PLC-ε activity, subsequent studies by Wing et al. implicated both 
Gα12 and Gα13 as regulators of PLC-ε-dependent inositol phosphate accumulation in COS-7 
cells [142].  Activation of PLC-ε by Gα12 and Gα13 occurs via a Ras-independent pathway as 
removal of the RA domains does not inhibit increased PLC-ε activity by Gα12 or Gα13.  
Several well defined downstream effectors of Gα12/13 are Rho-family GEFs (i.e. 
p115RhoGEF and LARG), which activate Rho-family GTPases, suggesting Gα12/13 may 
regulate PLC-ε indirectly through the activation of Rho GTPases [143-146].  Indeed, 
expression of C3 toxin, which ADP-ribosylates and inactivates Rho GTPases, with Gα12 or 
Gα13 inhibited PLC-ε-dependent inositol phosphate accumulation, but did not inhibit Gαq 
activation of PLC-β [147].  In addition to Gα-subunits, coexpression of heterotrimeric Gβγ 
dimers with PLC-ε increases the accumulation of inositol phosphates in COS-7 cells [131].  
Heterotrimeric Gβγ subunit regulation of p114RhoGEF potentially stimulates PLC-ε activity 
through downstream activation of Rho GTPases [148].  Whether the activation of PLC-ε by 
heterotrimeric Gα12, Gα13, Gβγ-subunits is direct has yet to be elucidated.   
Rho Family GTPases 
 Shortly after Gierschik and colleges identified PLC-β2 as a direct downstream 
effector of activated Rac GTPases, Wing et al. provided evidence that Rho-family GTPases 
also regulate PLC-ε activity [142].  When coexpressed with PLC-ε in COS-7 cells, 
constitutively active mutants of RhoA, RhoB, and RhoC markedly increased the 
accumulation of inositol phosphates in a PLC-ε-dependent manner.  Other Rho family 
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 GTPases, specifically Rac1, Rac2, Rac3, and Cdc42, failed to increase the activity of PLC-ε 
in the same experiments.  Removal of the PH domain of PLC-ε did not inhibit Rho-mediated 
inositol phosphate accumluation, suggesting a unique mechanism of regulation compared to 
Rac-mediated regulation of PLC-β.  Additionally, truncation of the RA1 and RA2 domains of 
PLC-ε results in an enzyme insensitive to Ras GTPases but that retains ability to be regulated 
by Rho GTPases.  Truncation of the amino- and carboxy-terminal regions of PLC-ε narrowed 
the Rho-mediated effector region to the catalytic core of PLC-ε, specifically a location 
between the EF-hand repeats and the C2 domain. 
 To define the region within PLC-ε required for enzyme regulation by Rho family 
GTPases, multiple sequence alignments were performed against the other PLC isoforms.  
Sequence comparisons identified a unique insert within the Y-box of the catalytic region of 
PLC-ε not found in other PLC isoforms.  Removal of the unique 70 amino-acid region within 
the Y-box of PLC-ε results in the loss of Rho-dependent enzyme activiation, but not the loss 
of H-Ras or Gβγ activation [142].  GST pull-down assays showed direct association of wild-
type, and Y-box deleted, PLC-ε with GTP-bound GST-RhoA and GST-H-Ras, but no 
interaction with GST-Rac, which specifically interacted with PLC-β2 in a GTP-dependent 
manner.  These results suggest the Y-insert region is sufficient for Rho-mediated PLC-ε 
activation; however, a complete loss of RhoA binding was not observed.  The identification 
of the required regions within PLC-ε for Rho and Ras activation suggests PLC-ε is 
potentially a direct, independent and dual effector of Rho and Ras GTPases. 
Receptor Regulated Activation 
 Several potential pathways involved in PLC-ε regulation have been identified using a 
combination of transfection and reconstitution experiments; however, these experiments do 
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 not identify extracellular signals and/or receptors involved in PLC-ε regulation.  As Gα12/13 
overexpression increases PLC-ε activity, so does activation of GPCRs (G protein coupled 
receptors) coupled to Gα12/13.  Studies by Hains et al. showed increased PLC-ε activity in 
cells expressing the LPA (lysophosphatidic acid) or PAR1 (protease activated receptor) 
treated with LPA or SFLLRN, respectively [147].  Additionally, these experiments 
confirmed Gα12/13-mediated activation of PLC-ε occurs through activation of Rho-family 
GEFs, specifically p115RhoGEF.  Expression of the RGS domain of p115RhoGEF, which 
binds to Gα12/13, inhibited the receptor-mediated stimulation of PLC-ε by LPA or thrombin 
receptors.  Likewise, expression of C3 toxin inhibited PLC-ε-dependent inositol phosphate 
formation following LPA or PAR1 receptor stimulation.  Similar studies by Kelley and 
colleagues showed similar receptor mediated PLC-ε activation, with the addition of the S1P 
(sphingosine 1-phosphate) receptor, another Gα12/13 coupled receptor [140].  CD44, a 
hyaluronan receptor coupled to LARG (Leukemia-associated RhoGEF) also increases the 
activity of PLC-ε, presumably through activation of Rho GTPases [149].   
 Work by Schmidt and colleagues identified additional GPCRs coupled to Gαs-
subunits that regulate PLC-ε activity downstream of activated Rap GTPases.  Receptors 
coupled to heterotrimeric Gαs subunits, such as the β2-adrenergic or prostaglandin E1 
receptors, stimulate adenylyl cyclase resulting in an increase in cAMP [150].  The 
accumulation of cAMP stimulates the cAMP-dependent GEF, EPAC (exchange protein 
activated by cAMP), which specifically activates Rap2B.  Increased PLC-ε activity in cells 
simulated with Gαs-coupled receptor agonists mimicked the activity observed with EPAC 
overexpression, confirming the hypothesized Rap2B-dependent pathway.  In contrast, 
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 GPCRs that couple to Gαi pathways, which inhibit adenylyl cyclase, decreased activated 
Rap2B and inhibited PLC-ε activity [151].    
In addition to GPCR-mediated PLC-ε activation, several growth factor receptors have 
been shown to regulate PLC-ε activity.  Following receptor stimulation, RasGEFs are 
recruited to autophosphorylated residues on the receptors, resulting in nucleotide exchange 
and activation of Ras GTPases.  Indeed, activation of EGF or PDGF receptors in cells 
expressing PLC-ε leads to increased inositol phosphate accumulation [128;140;152].  
Regulated PLC-ε activity is believed to be a direct consequence of Ras and/or Rap activation 
as removal of the RA domains of PLC-ε abolishes growth factor receptor-mediated activity.  
Upstream regulation of PLC-ε activity by such a multitude of receptors places PLC-ε at the 
nexus of multiple signaling pathways involving both heterotrimeric and monomeric 
GTPases.  The physiological consequences of regulated PLC-ε activity become increasingly 
relevant as more pathways linked to PLC-ε regulation are discovered. 
1.5.4 Physiological Function of PLC-ε 
 The presence of 14 mammalian PLC isoforms performing the same enzymatic 
reaction would suggest potential redundancy or compensatory action upon genetic 
manipulation or inactivation of specific PLC isoforms.  Unique expression patterns for each 
PLC isoform may account for regulated function of individual isoforms, and molecular 
studies of regulation have provided significant advances in understanding the pathways 
involved in PLC regulation.  To provide a more detailed understanding of the physiological 
role of PLC-ε, several groups have manipulated or knocked-out PLC-ε genes.  In the first 
such study, Kataoka and colleagues deleted the PLC210 gene in C. elegans, plc-1 [153].  
Ovulation and fertility in C. elegans is regulated by an Ins(1,4,5)P3-dependent signaling 
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 pathway activated upstream by LET-23, a receptor tyrosine kinase.  Deletion of plc-1, a gene 
encoding an enzyme that catalyzes the formation of Ins(1,4,5)P3, is potentially involved in 
ovulation and fertility.  Indeed, removal of catalytically required regions of PLC210 resulted 
in reduced fertility due to ovulation defects.  These studies provided the first example of the 
physiological function of PLC-ε in an intact organism. 
 Kataoka and colleagues also created mice expressing inactive PLC-ε by removing 
portions of the catalytic X-box (PLC-ε∆X/∆X) [154].  Studies exploring the onset of skin 
carcinomas revealed a crucial role for PLC-ε downstream of Ras-induced de novo 
carcinogenesis.  Mice lacking catalytic PLC-ε function exhibited delayed average time of 
onset and reduced incidence of skin tumors in response to chemical carcinogens.  Tumors 
that did form were generally smaller in size, contained fewer cells, and failed to undergo 
malignant progression into carcinomas.  Additionally, tumors formed in PLC-ε∆X/∆X mice 
failed to undergo basal layer cell proliferation and epidermal hyperplasia in response to 
chemical carcinogens.  Activated H-Ras was found in all cancer cells, regardless of PLC-ε 
background, suggesting a critical role for PLC-ε in tumor development and progression 
downstream of Ras signaling.     
 PLC-ε∆X/∆X mice were also used to study the role of PLC-ε enzyme activity in cardiac 
defects.  Although pups were otherwise normal, they displayed enlarged hearts resulting from 
congenital malformation of the aortic and pulmonary valves [155].  The defects in valve 
formation caused a mild degree of stenosis and varying degrees of regurgitation resulting in 
ventricular dilation.  Whereas normal mice undergo remodeling of valves during the 
formation of slender leaflets, mice lacking PLC-ε activity showed increases in valve 
thickness due to an increased number of cells.  These results suggest a role for PLC-ε in 
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 proliferation and/or apoptosis in semilunar valve cells during the late stages of 
valvulogenesis.  This phenotype is shared in mice with attenuated EGF receptor signaling 
and in mice lacking the heparin-binding EGF-like receptor, suggesting a crucial role for 
PLC-ε activity during cardiac valve formation downstream of EGF-mediated Ras or Rap 
activation.   
 A second mouse model created by Wang and colleagues removed the entire PLC-ε 
gene to study the role of PLC-ε in cardiac function [156].  PLC-ε expression in cardiac 
myocytes is upregulated at both the protein and mRNA levels in patients undergoing heart 
failure, as well as in two mouse models of cardiac hypertropic stress.  PLC-ε-/- mice showed 
decreased cardiac function, decreased response to isoproterenol, reduced calcium response 
resulting from β-adrenergic receptor activation in cultured cells, and mice are more likely to 
develop cardiac hypertrophy in response to chronic stress.  These data, combined with the 
fact that no other PLC isozymes are upregulated in PLC-ε-/- mice, suggests PLC-ε is required 
for maintenance of maximum contractile reserve in response to β-adrenergic signaling under 
conditions of cardiac stress.  The increased expression of PLC-ε may be a compensatory 
mechanism in response to the desensitization of β-adrenergic receptors during heart failure.  
Previous studies, as addressed above, indicate β-adrenergic stimulation of a Gαs pathway, 
increasing cAMP, leading to activation of EPAC and Rap2B.  It has yet to be determined if 
this pathway is responsible for the PLC-ε-dependent signaling observed in the PLC-ε-/- 
mouse model.  
 A recent study has identified naturally occurring mutations of PLC-ε in human 
patients suffering from nephrotic syndrome [157].  Nephrotic syndrome is characterized by 
proteinuria, hypoalbuminermia, and edema, often leading to end-stage kidney disease, 
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 requiring dialysis or kidney transplantation for survival.  A whole-genome search performed 
to identify causative genes involved in nephrotic syndrome revealed seven different 
homozygous PLC-ε mutations.  Six of the identified mutations were either nonsense or 
frameshift mutations, with the additional mutation causing a missense mutation of amino 
acid 1484 from serine to leucine within the catalytic X-box.  Of the 12 patients identified 
with PLC-ε mutations, 9 developed end-stage kidney disease by the age of 5, suggesting an 
essential role for PLC-ε in preventing severe nephrotic syndrome.  Interestingly, two of the 
identified patients responded to treatment with corticosteroids or cyclosporin A, representing 
the first case of a molecular cause of nephrotic syndrome that was responsive to therapy.   
1.6 Guanine nucleotide binding proteins 
 Guanine nucleotide binding proteins, or G proteins, are a family of GTP hydrolases 
sharing a common structural core [158].  The >150 eukaryotic GTPases are grouped into two 
superfamilies; the smaller Ras-like proteins, and the heterotrimeric Gα-subunits.  Both 
families of GTPases act as binary molecular switches that are activated by the tensioned 
binding of GTP, resulting in conformational changes within the switch regions favorable for 
association with downstream effector proteins.  The hydrolysis of GTP to GDP returns the 
switch G protein switch regions to the “off” position, relaxing the switch regions and 
terminating downstream effector interactions.  The exchange of GTP and the subsequent 
hydrolysis to GDP is controlled by a high affinity for guanine nucleotides, the intrinsic 
activity of the GTPase, and by various regulator proteins such as guanine nucleotide 
exchange factors (GEFs) and GTPase-accelerating proteins (GAPs) as discussed below 
(Figure 1.4).  
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  The conserved structural domain shared among all G proteins is an approximately 20 
kDa G domain, which is a variation of a classical nucleotide-binding fold [159].  The G 
domain fold consists of a six-stranded β-sheet surrounded by α-helices.  Four structural 
elements within this region serve a common purpose in all G proteins: a rigid phosphate-
binding loop (P-loop), which contacts the α- and β-phosphates on the guanine nucleotide and 
utilizes a serine or threonine to coordinate a Mg2+ ion; the switch I region, which aids in 
Mg2+ coordination; switch II, which is the GTP γ-phosphate sensor and binding site, and 
contains a catalytic glutamine residue present in most G proteins; and a conserved NKXD 
sequence for recognition of the guanine ring of the nucleotide [160;161].  Although the 
mechanism of GTP hydrolysis by GTPases remains a point of conjecture, the reaction is 
believed to involve the in-line nucleophilic attack of water upon the γ-phosphate group, 
deprotonation of the attacking water molecule, formation of a transition state complex, and 
release of Pi [162;163].  Evidence suggests the γ-phosphate group is the catalytic base for the 
reaction and that Mg2+ is required to increase the basicity of the γ-phosphate [164;165]. 
1.6.1 Ras Superfamily GTPases  
 Small GTPases are monomeric G proteins with molecular masses ranging from 20 to 
40 kDa and that exist in eukaryotes ranging from yeast to human.  Like all G proteins, 
monomeric G proteins have consensus sequence specifying interactions with guanine 
nucleotides.  Over 150 small G proteins are encoded in the human genome, which make up 
the Ras superfamily of GTPases [166].  Members of the Ras superfamily are structurally 
classified into five different families: the Ras, Rho, Rab, Arf, and Ran families.  Among 
subfamilies, Ras proteins share approximately 50-55% homology, but are less conserved, 
approximately 30%, between families [167;168].  Ras superfamily GTPases are implicated in 
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 an extensive array of cell biological processes regulated by many upstream activators, 
downstream effectors, and negative regulators.  All Ras family GTPses are structurally 
similar and bind effectors through interactions with the switch regions.  However, distinct 
intracellular localizations and interaction with specific downstream effectors accounts for 
functional specificity of various Ras family GTPases.   
Ras GTPases 
 The most highly studied and founding members of the Ras superfamily are the Ras 
proteins (rat sarcoma), including the classical Ras proteins (H-, K-, and M-Ras), the Rap 
proteins (Rap1A, 1B, 2A, 2B), and Ral proteins.  H-Ras and K-Ras genes were first 
identified as oncogenes in sarcoma viruses during the late 1970s and the cellular oncogenes 
were found in several human carcinomas [169-171].  The carboxy-terminal end of most Ras 
GTPases contains a CAAX (C=Cys, A=aliphatic, X= any amino acid) region comprising the 
membrane targeting sequence.  Farnesyltransferase or geranylgeranyltransferase I recognize 
the CAAX motif and catalyze the covalent attachment of a farnesyl or geranylgeranyl 
isoprenoid, respectively, to the Cys residue of the tetrapeptide motif [172-174].  The 
specificity of transferases is predicated by sequence within, or surrounding, the CAAX motif, 
which are classified into two main groups.  The first group, including H- and N-Ras, contains 
an additional Cys residue upstream of the CAAX motif, which is palmitoylated.  Other 
farnesylated Ras GTPases, including K-Ras, have a polybasic stretch of amino acids directly 
upstream of the CAAX motif.  The second type of lipid modification, including the Rap 
GTPases, recognizes Leu or Phe in the X-position resulting in geranylgerynlation of the Cys 
CAAX residue.  Following attachment of a lipid moiety, the -AAX portion of the CAAX 
motif is proteolytically removed and the exposed cysteine residue is carboxymethylated. 
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 Attachment of an isoprenoid moiety is not sufficient for proper trafficking of Ras GTPases to 
lipid membranes, but requires the additional palmitoylation (i.e. H-Ras) or polybasic amino 
acids (i.e. K-Ras) [175]. 
 A large number of extracellular signaling molecules activate Ras family guanine 
nucleotide exchange factors (GEFs) leading to the formation of active, GTP-bound Ras 
proteins [176;177].  A complex between the CDC25 catalytic domain of the RasGEF SOS 
(Son of Sevenless) and H-Ras revealed information regarding the catalytic activity of 
nucleotide exchange [178].  Binding of the CDC25 domain to H-Ras induces conformational 
changes in the switch regions opening the nucleotide binding pocket, thereby reducing the 
affinity for Mg2+ and the nucleotide phosphate groups, and stabilizing the GTPase in a 
nucleotide-free conformation.  Once the nucleotide binding pocket is opened and GDP is 
released, the molar excess of GTP over GDP in the cell results in activation of the GTPase 
through binding GTP. 
 Termination of Ras signaling is achieved by hydrolysis of GTP to GDP.  Ras family 
GTPases have a notoriously slow intrinsic rate of hydrolysis (kcat ~0.02 min-1), which is aided 
by various RasGAPs (Ras-family GTPase activating proteins) [179].  The crystal structure of 
p120GAP in complex with H-ras provided extensive information regarding the mechanism 
by which RasGAPs aid in GTP hydrolysis [180].  Whereas heterotrimeric Gα-subunits bind 
aluminum fluoride in the presence of GDP, mimicking the transition state of hydrolysis, Ras 
GTPases lack a critical arginine residue provided in trans by RasGAPs.  The structure of 
p120GAP in complex with GDP-bound Ras and aluminum fluoride suggests the trans 
arginine provides a strong hydrogen bond donor to the nucleotide binding pocket and 
stabilizes the catalytic conformation of the Gln side-chain in the switch II region. 
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  Genuine Ras effectors are characterized by at least one of three distinct ~100 amino 
acid folds: two different Ras-binding domains (RBD) or Ras-association (RA) domains.  
Although sequence homology among Ras-interacting domains varies greatly, all three 
domains form a similar ubiquitin-like superfold [181].   Activated Ras GTPases regulate a 
diverse cascade of signaling pathways, including the widely studied activation of MAP 
kinase pathways after stimulation of growth factor receptors, ultimately leading to gene 
transcription.  Ras GTPases are also involved in lipid metabolism through activation of PI3K, 
which phosphorylates PtdIns(4,5)P2 to generate PtdIns(3,4,5)P3 [182].  Various other studies 
have implicated classical Ras proteins in cell proliferation, differentiation, morphology, and 
apoptosis [183-186].  Other Ras family proteins, such as Rap, Ral, or R-Ras, possess unique 
functions independent of the function of classical Ras GTPases.  Most relevant to this work is 
that in addition to H-, K-, and N-Ras, Rap GTPases have been shown to regulate the activity 
of PLC-ε in an RA2 dependent manner [128;187]. 
Rho GTPases 
 Rho GTPases are monomeric GTPases characterized by an α-helical “insert region” 
(amino acids 125-135 in Rac) not present in Ras family GTPases [188;189].  Based on 
sequence and function, 22 mammalian Rho GTPases have been identified, which are divided 
into 5 groups: the Rho-like (RhoA, RhoB, and RhoC), the Rac-like (Rac 1, Rac2, Rac3, and 
RhoG), the Cdc42-like, Rnd, and RhoBTB subfamilies.  With the exception of the Rnd 
proteins, which are constitutively active due to inability to hydrolyze GTP, all Rho family 
GTPases are regulated by GDP/GTP cycling.  The most extensively characterized Rho 
GTPases are RhoA, Rac1, and Cdc42 which cause the formation of stress fibers, 
lamellipodia, and filopodia, respectively [190-192].  Like Ras-family GTPases, most Rho 
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 GTPases contain a carboxy-terminal CAAX motif resulting in covalent attachment of 
farnesyl or geranylgeranyl lipid moieties, cleavage of the -AAX sequence, and 
carboxymethylation of the cysteine residue.  Post-translational modification of Rho family G 
proteins enhances membrane association and leads to distinct cellular localizations 
[193;194]. 
 The activation of Rho family GTPases is regulated by a large family of RhoGEFs, 
which catalyze the exchange GDP for GTP.  Unlike the relatively small number of RasGEF 
proteins, over 60 RhoGEFs have been identified, which are broken down into three families 
[195].  The Dbl family RhoGEFs represent the largest subfamily of exchangers, containing a 
catalytic Dbl homology (DH) domain followed by a PH domain, which aids in membrane 
localization and/or cooperates with the DH domain to assist nucleotide exchange.  Some 
RhoGEFs are fairly promiscuous, exchanging on several Rho family GTPases, whereas other 
appear to confer specificity of exchange (reviewed:[196;197]).  The regulated activity of 
RhoGEFs ultimately leads to the activation of Rho-family signaling pathways, which has 
prompted intense characterization of upstream signaling pathways.  Growth factor receptor 
activation, which leads to the activation of Ras family GTPases can lead to the activation of 
Rho GTPases through the activation of several RhoGEFs, including Tiam1 [198].  Activation 
of hepthahelical receptors also leads to Rho GTPase activation through RhoGEFs that 
encompass an RGS (regulator of G protein signaling) domain for heterotrimeric Gα-subunits 
in addition to a DH/PH exchange region.  Specifically, activated Gα12/13 family members 
engage the RGS box of p115-RhoGEF or LARG, leading to the termination of heterotrimeric 
signaling and the activation of Rho family GTPases.  The integration of multiple signaling 
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 pathways through RhoGEFs suggests Rho family GTPases mediate a multitude of cellular 
responses.     
 Rho family GTPases are negatively regulated by GAP proteins and RhoGDIs 
(guanine nucleotide dissociation inhibitors).  RhoGAP proteins share a ~140 residue GAP 
domain, which enhances the rate of GTP hydrolysis and share no resemblance to RasGAPs 
[199].  Several RhoGAPs display substrate specificity for Rho family GTPases, while others 
are more promiscuous [200].  RhoGDIs bind to GDP-bound Rho GTPases through an 
immunoglobin-like domain and inhibit GDP/GTP exchange [201;202].  Additionally, 
RhoGDIs contain a hydrophobic pocket which accommodates the isoprenoid group attached 
to the GTPase [203].  Masking of the lipid group allows the Rho/RhoGDI complex to exist in 
the cytoplasm, sequestering the GTPases from membrane associated activators and effectors.  
 The main function of Rho family GTPases is to regulate the assembly and 
organization of the actin cytoskeleton.  A large number of cellular processes depend on Rho-
mediated actin cytoskeleton dynamics, including cytokinesis, phagocytosis, pinocytosis, cell 
migration, and axon guidance [204-207].  The majority of Rac and Cdc42 effectors contain a 
CRIB (Cdc42/Rac-interactive binding) domain that recognizes the switch regions of the 
GTPase [208;209].  Other Rac/Cdc42 effectors utilize other regulatory domains to bind the 
switch regions of the GTPases (e.g. the PH domain of PLC-β).  Many Rho effectors contain a 
REM (Rho effector homology) region, which contains a three leucine-zipper like motif [210].  
In context of the current work, several emerging Rho family effectors involved in 
phospholipid metabolism are especially intriguing.  The ability of Rho GTPases to regulate 
PLC enzymes, though a relatively new observation, increases the complexity of Rho family 
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 GTPase signaling.  Additionally, several PI kinases are regulated by Rho family GTPases, 
which may result in amplified PLC signaling because of increased substrate levels [211].   
Rab, Ran, and Arf GTPases  
 The largest family of Ras GTPases are the Rab proteins (Ras-like proteins in the 
brain), with 61 total members [212].  Rab proteins are localized to specific intracellular 
compartments based on prenylation and divergent carboxy-terminal sequences.  The 
localization of specific Rab GTPases is essential for the regulation of intracellular vesicular 
transport and trafficking proteins between different organelles in the endocytic and secretory 
pathways [213].  Ran GTPases (Ras-like nuclear) are the most abundant small GTPases in 
the cell and are involved in nucleocytoplasmic transport of RNA and proteins [214].  
Regulated activation of Ran proteins have also been implicated in mitotic spindle assembly, 
DNA replication, and nuclear envelope assembly [215].  Arf proteins are localized to the 
Golgi apparatus and are involved in vesicle formation.  The regulation of Arf proteins is 
somewhat unique in that when bound to GDP, Arf proteins are cytoplasmic, and upon 
nucleotide exchange, the myristoylated amino-terminal helix is exposed, allowing association 
with lipid membranes [216].   
1.6.2 Heterotrimeric G proteins 
 In the late 1950s and early 1960, Sutherland and Rall were able to show hormone 
stimulated production of cAMP.  However, the mechanism of hormone-promoted cAMP 
production remained elusive [217].  Years later, Rodbell and colleagues discovered the 
requirement for GTP in adenylyl cylase simulation [218].  Finally, Ross and Gilman bridged 
the gap by showing G protein-mediated communication between β-adrenergic receptor 
activation and stimulation of adenylyl cyclase [219].  There are 16 known Gα genes encoding 
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 23 known Gα-subunits divided into four major classes: Gαs, Gαi, Gαq, and Gα12/13 [99].  In 
addition to the core “Ras-like” domain, Gα subunits contain a helical domain resulting in an 
additional switch III loop. When bound to GDP, Gα subunits form a heterotrimer through 
association with an obligate Gβγ heterodimer.  The heterotrimeric complex of Gα and Gβγ 
negatively regulates signaling due to the tight association of the proteins in the GDP-bound 
state, with Gβγ dimers serving as guanine nucleotide dissociation inhibitors, or GDIs.  There 
are five ~35 kDa Gβ subunits and fourteen ~8 kDa Gγ subunits, which associate in various 
combinations to form heterodimers.  Both Gα- and Gγ-subunits are modified by attachment 
of lipid moieties, resulting in membrane associations of both Gα- and Gγ-subunits.  All Gα-
subunits, with the exception of transducin, have an amino-terminal 16-carbon palmitate 
attached through a thioester bond to a cysteine residue [220].  Additionally, Gαi family 
members undergo co-translational N-myristolyation to an amino-terminal glycine, followed 
by removal of the initiator methionine.  Three Gγ-subunits have a 15-carbon farnesyl moiety 
attached (Gγ1, Gγ8, and Gγ11) and the remaining Gγ-subunits have a 20 carbon 
geranylgeranyl group attached.   
 Heterotrimeric G proteins are associated with signaling directly downstream of the 
approximately 865 genes that encode GPCRs.  The specificity of G proteins for GPCRs is 
conferred through five amino acids at the carboxy-terminus of Gα-subunits.  Extracellular 
ligand binding to GPCRs causes an intracellular conformational change of the receptor 
stimulating GEF activity on Gα-subunits.  The GEF activity of the receptor most likely 
promotes the release of GDP by stabilizing the nucleotide-free state of the Gα subunit, which 
then binds GTP due to the molar excess of GTP over GDP in cells.  GTP binding causes 
conformational changes within the three switch regions of Gα leading to the dissociation of 
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 Gβγ.  Activated Gα subunits and liberated Gβγ subunits initiate downstream signals by 
interacting with specific effector proteins.  Signaling is terminated by hydrolysis of GTP to 
GDP by the Gα subunit and reassociation of the heterotrimer complex.  Gα-subunits display 
the highest intrinsic rate of hydrolysis among G proteins (kcat ~ 2-5 min-1) due the presence of 
a conserved arginine residue that is absent in Ras-family GTPases, which stabilizes the 
transition state of GTP hydrolysis [221].  
 The rate of GTP hydrolysis by Gα-subunits is not fast enough to account for 
physiological rates of signal transduction.  Several Gα effector proteins, including PLC-β1, 
act as GAPs to increase the rate of GTP hydrolysis by Gα-subunits [222].  Additionally, a 
family of RGS proteins negatively regulate heterotrimeric G proteins signaling by increasing 
the rate of GTP hydrolysis at least 50-fold [223-225].  RGS proteins bind directly to the 
switch regions of Gα-subunits, locking the protein in the transition state for GTP hydrolysis.  
RGS proteins are often multifunctional proteins containing elaborate domains not involved in 
GAP activity.  Most relevant to this work are the Rho family GEFs containing an RGS 
domain that serve as specific GAPs for Gα12/13 family members, but also contain a RhoGEF 
domain to activate Rho family GTPases.  
1.7 Research Goals 
Phospholipase C enzymes generate the second messengers Ins(1,4,5)P3 and DAG by 
hydrolyzing the minor membrane lipid PtdIns(4,5)P2.  The complexity of inositol lipid 
signaling has recently been extended with the identification of Ras superfamily GTPase-
mediated regulation of PLC isozymes.  Perhaps the most unique example of functionally 
complex regulation of phospholipase C occurs in the recently discovered isozyme PLC-ε, 
which is activated in vivo after overexpression of various small GTPases within the Rho and 
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 Ras families through at least two distinct domains.  Measuring inositol phosphate 
accumulation in cells overexpressing PLC isoforms with potential activators provides a 
powerful tool for identifying pathways that regulate PLC activity.  However, coexpression 
experiments cannot unquestionably identify proteins that regulate PLC function via direct 
protein-protein interactions.  The overall goals of the following research is to use purified 
proteins to establish unambiguously the direct activation of PLC-ε by small GTPases within 
the Rho and Ras families and to establish the enzymatic consequences of the interaction of 
multiple G proteins with PLC-ε.  To this end, we will attempt to purify a catalytically active 
fragment of PLC-ε and determine the enzymatic characteristics of the enzyme.  Regulation of 
the activity of PLC-ε by various G proteins will be studied by reconstitution of purified 
proteins in a model phospholipid vesicle system.  These experiments will provide the first 
information regarding proteins that directly interact with PLC-ε to regulate the functional 
activity of the enzyme. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45
  
 
 
 
 
 
 
 
 
 
Figure 1.1. Synthesis and metabolism of phosphoinositides.  Phosphatidylinsitol is the 
precursor to all of the phosphoinositides.  The basic structure of phosphatidylinositol is 
composed of a di-esterified glycerol lipid moiety connected via a di-ester phosphate bond to 
the D1 position of myo-inositol.  The five free hydroxyl groups are regulated by the 
attachment of mono-ester phosphate groups at various positions on the inositol ring.  Several 
lipid kinases (blue) recognize specific hydroxyl groups on the inositol ring and transfer a γ-
phosphate from ATP to the inositol ring.  The action of the lipid kinases is antagonized by 
several lipid phosphatases (red) which remove specific phosphate groups from the inositol 
headgroup. 
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Figure 1.2. Domain organization of mammalian phospholipase C (PLC) family 
members.  The six subfamilies of PLCs share common structural and regulator motifs, 
which are denoted by similar color.  All PLC isozymes contain the canonical domains found 
in the evolutionarily conserved PLC-δ, including a pleckstrin homology (PH) domain 
(excluding PLC-ζ), a series of four EF-hand domains, a catalytic TIM barrel, and a C2 
domain.  Elaboration of the conserved catalytic regions by various modular domains gives 
rise to the different PLC subfamilies.  PLC-ε contains a Ras guanine nucleotide exchange 
domain (RasGEF), tandem carboxy-terminal Ras association (RA) domains, and a Cysteine-
rich (Cys) region.  The four PLC-β isozymes contain a carboxy-terminal (CT) domain 
necessary for dimerization and regulation by Gαq.  The catalytic region of PLC-γ is 
interrupted by the presence of a split PH domain and an array of Src-homology (SH) 2 and 3 
domains, which confer enzyme activity downstream tyrosine kinases.  PLC-η contains a 
region rich in Ser/Pro (S/P), however, the role of this region in enzyme regulation is not 
determined. 
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Figure 1.3.  PLC-ε links heterotrimeric and small G protein signaling pathway in the 
generation of second messengers.  The phospholipase activity of PLC-ε is downstream of 
an ever increasing number of signaling pathways integrating heterotrimeric and small G 
proteins.  Activation of transmembrane receptors that activate Gα12/13, Rho, and Ras 
GTPases are implicated in the activation of PLC-ε.  More well characterized pathways are 
indicated by bolder lines with significant evidence for the direct modulation of PLC-ε 
activity by several Ras family proteins, as well as Rho family members.  Proposed regulatory 
pathways (dashed grey lines) involved the undefined activation of PLC-ε by heterotrimeric 
Gα12/13 and/or Gβγ-subunits.  Additionally, PLC-ε potentially regulates a positive feedback 
loop RasGEF-promoted activation of Ras GTPases activated PLC-ε through binding the 
carboxy-terminal RA domains. 
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Figure 1.4.  Model of regulated nucleotide cycling of G proteins.  An large number of 
extracellular stimuli interact with transmembrane receptors to activate guanine nucleotide 
exchange factors (GEFs) resulting in the exchange of GDP for GTP on heterotrimeric and 
monomeric GTPases.  The action of GEFs is inhibited by guanine dissociation inhibitors 
(GDIs) that bind GDP-bound GTPases and inhibit nucleotide exchange and/or sequester 
GTPases in the cytoplasm.  Once activated, GTP-bound G proteins recognize downstream 
effectors to initiate diverse signaling cascades.  The cycle returns to the basal state when the 
the GTPase hydrolyzes the γ-phosphate of GTP.  Because of the relatively slow intrinsic rate 
of hydrolysis, the majority of G proteins are aided by GTPase-accelerating proteins (GAPs).   
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Table 1.1. Tissue distribution and function of mammalian PLC isoforms (adapted from 
[226]) 
 
Isozyme   Tissue Distribution   
Function in KO 
mice Ref. 
PLC-β1   
brain (cerebrum, hippocampus)   
adrenal gland, lung, parotid 
gland 
  induction of epilepsy [55;65] 
PLC-β2 
  
hematopoietic cells (neutrophil, 
platelet)   
chemoattractant-
induced superoxide 
production 
[96] 
PLC-β3 
  
brain, liver, parotid gland, 
platelet   
µ-opioid-mediated 
responses [88;97] 
PLC-β4 
  
brain (cerbellum, retina)  
 
visual response, 
ataxia, long-term 
depression 
[65;98;227] 
         
PLC-δ1   brain, heart, lung, testis     [55] 
PLC-δ3   skeletal muscle, heart, brain     [55] 
PLC-δ4 
 
testis, brain, skeletal muscle  
 
acrosome reaction in 
sperm [89;90;228] 
           
PLC-γ1   lung, thymus, brain (neuron)   embryonic lethality [55;117;229] 
PLC-γ2   spleen, thymus, lung   B cell development [55] 
           
PLC-ε 
  
lung, liver, heart, skeletal 
muscle  
 
cardiac function, 
isoproterenol 
response, calcium 
response 
[129;130;156] 
         
PLC-ζ   sperm     [119] 
           
PLC-η1   
brain (hippocampus, Purkinje 
cells)     [124] 
PLC-η2 
  
brain (hippocampus, cerbral 
cortex, olfactory bulb)     
[122] 
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 CHAPTER 2 
 
DIRECT ACTIVATION OF PURIFIED PHOPHOLIPASE C EPSILON BY 
RHOA STUDIED IN RECONSTITUTED PHOSPHOLIPID VESICLES 
 
2.1  Abstract 
Phospholipase C-ε (PLC-ε) was shown recently to be a downstream effector of Rho 
GTPases, and we have utilized an in vitro phospholipid vesicle reconstitution system with 
purified proteins to show this regulation to be direct.  This chapter describes high-level 
expression of a hexa-histidine-tagged fragment of PLC-ε encompassing the catalytic core of 
the enzyme through the tandem RA domains using a recombinant baculovirus and High Five 
insect cells.  The recombinant protein is purified to homogeneity using metal chelate affinity 
and size exclusion chromatography.  The small GTPase RhoA also is expressed to high 
levels in a lipidated form after baculovirus expression in High Five cells and is purified to 
near homogeneity after detergent extraction and metal chelate affinity chromatography.  The 
capacity of GTPγS-bound RhoA to stimulate the phospholipase activity of PLC-ε is assessed 
by reconstitution of the RhoA in PtdIns(4,5)P2 substrate-containing phospholipid vesicles. 
2.2  Introduction    
An extensive array of extracellular signaling molecules including hormones, 
neurotransmitters, and growth factors elicit their physiological effects through receptor-
mediated stimulation of phospholipase C (PLC) [48;56].  PLC enzymes respond by 
hydrolyzing the minor membrane phospholipid PtdIns(4,5)P2 into the second messenger 
 molecules inositol (1,4,5)-trisphosphate and diacylglycerol, which are responsible for the 
release of Ca2+ from intracellular stores and the activation of protein kinase C, respectively.   
 The six PLC isoforms (PLC-β, -γ, -δ, -ε, -ζ, and –η ; Fig 1) are characterized by the 
presence of conserved X- and Y-boxes, which fold together to form a triose-phosphate 
isomerase (TIM) barrel and the catalytic core of the enzyme [76].  These isozymes are 
differentially elaborated with structural/regulatory domains outside of the catalytic region.  For 
example, the two PLC-γ isozymes contain SH2 and SH3 domains and are subject to regulation 
by tyrosine kinases [112;113], and the four PLC-β isozymes contain a long carboxy terminal 
domain that confers capacity to bind and be activated by Gα subunits of Gq family of 
heterotrimeric G proteins [101-103]. 
 Kataoka and colleagues first identified PLC-ε as a Ras-binding protein in C. elegans 
[127], and subsequent work from the laboratories of Kataoka [133], Lomasney [129], and 
Kelley and Smrcka [130] revealed the presence of PLC- ε in mammalian tissues.  Two Ras-
associating (RA) domains in the carboxyl terminus of PLC- ε underlie direct regulation of this 
signaling protein by Ras and Rap [129;133;187] and a conserved CDC25 guanine nucleotide 
exchange (GEF) domain in the amino terminus provides a poorly understood mechanism 
whereby PLC- ε acts as an upstream regulator of Ras, Rap, and potentially other Ras 
superfamily GTPases [129;139].  Although heterotrimeric G proteins of the Gq family do not 
regulate the activity of PLC- ε, this isozyme is activated by Gα12 [129], Gα13 [131], and Gβγ-
subunits [131].  Regulation by these heterotrimeric G protein subunits may not be direct, and 
the fact that several RhoGEFs are effectors of Gα12/13 [144;145] suggested to us that Rho might 
be responsible for activation of PLC-ε by Gα12/13.  Indeed, RhoA, RhoB, and RhoC, but not 
Rac or Cdc42, markedly stimulate the lipase activity of PLC-ε after coexpression in COS-7 
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 cells [142].  Whereas truncation of the carboxy terminal RA domains of PLC-ε result in loss of 
regulation by Ras, the capacity of both Gα12/13 and Rho to activate PLC- ε is retained.  
Expression of C3 botulinum toxin, which ADP-ribosylates and inactivates Rho, results in 
concomitant loss of capacity of Rho, Gα12, Gα13, or LPA or thrombin receptor agonists (which 
activate Gα12/13 signaling pathways) to activate PLC-ε [147].  These data are consistent with 
the idea that heterotrimeric G protein-coupled receptors that activate Gα12/13 regulate PLC-ε 
through activation of a RhoGEF and conversion of Rho to its GTP-bound form.  Pull down 
experiments illustrating GTP-dependent interaction of RhoA with PLC-ε also were consistent 
with this possibility [230]. 
 To address whether PLC-ε is directly activated by Rho, we have developed an in vitro 
system that allows quantification of the enzymatic activity of purified PLC-ε and the capacity 
of PLC-ε to function as a direct effector for RhoA [231].  This article describes in detail 
methods for purifying to homogeneity a catalytically active fragment of PLC-ε, as well as 
methodology for the purification of lipidated RhoA.  In both cases we have generated a 
recombinant baculovirus, and expressed the PLC isozyme or RhoA to high levels using an 
insect cell expression system.  We also present methodology for quantification of the activity 
of this Rho effector enzyme using PtdIns(4,5)P2 substrate-containing phospholipid vesicles.   
Similar methodology for study of regulation of PLC-β2 by Rac has been described 
previously [232]. 
2.3  Materials and Methods 
Virus Preparation 
 Baculovirus encoding a fragment of PLC-ε encompassing the EF hand domains 
through tandem RA domains (PLC-ε EF-RA2: amino acids 1258 through 2215) was prepared 
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 by PCR amplification of the desired regions of rat PLC-ε and subsequent ligation into 
pFastBacHTb (Invitrogen), which incorporates a hexa-histidine affinity tag at the amino 
terminus of the coding sequence.  The human monomeric GTPase RhoA also was cloned into 
pFastBacHTb for viral propagation.  Viruses are amplified according to the manufacturer’s 
instructions, and the titer of the working stock viruses was approximately 7 x 107 pfu/ml.  
Working stock viruses are stored at 4oC in the dark.  Additional aliquots of P1 and P2 viral 
stocks are frozen at -80oC for long-term storage. 
Cell Culture 
 High Five cells (Invitrogen) are maintained in shaker flasks at 27oC with Express 
Five SFM supplemented with 10 mM L-glutamine.  Cell density is monitored daily and 
maintained between 0.8 and 4 x 106 cells/ml.  A day prior to infection, cells are diluted to a 
density of 0.8 x 106 cells/ml in a final volume of 1 L per 4 L shaker flask.  Cells are grown 
overnight in shaker flasks at 150 rpm and 27oC to reach a target density of ~2.0 x 106 
cells/ml the following day. 
PLC-ε EF-RA2 Purification 
Overexpression of recombinant protein is somewhat variable using a baculovirus 
expression system and optimal expression conditions are determined empirically.  In our 
experience, the PLC-ε EF-RA2 fragment is expressed to high levels after 48 hours of 
infection using a multiplicity of infection (MOI, number of virus particles per cell) of 1.  
 Four liters of High Five cells (~2.0 x 106 cells/ml) are infected with working stock 
virus encoding hexa-histidine-tagged PLC-ε EF-RA2.  Forty-eight hours postinfection, cells 
are harvested by centrifugation at 1,000g for 10 min in a J6 Beckman swinging bucket 
centrifuge at 4oC.  All buffers and subsequent steps during the purification should be at 4oC.  
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 Cells are resuspended in 100 ml of lysis buffer (lysis buffer: 20 mM HEPES, pH 8, 300 mM 
NaCl, 15 mM imidazole, 1 mM CaCl2, 1 mM β-mercaptoethanol (β-ME), 10 % glycerol, and 
2 EDTA-free complete protease inhibitor tablets (Roche Applied Sciences)) and lysed using 
an EmulsiFlex C5 cell homogenizer (Avestin).  Cell lysate is cleared of intact cells and nuclei 
by low-speed centrifugation (500g, 15 min, J6 Beckman centrifuge).  The supernatant from 
the low-speed spin is centrifuged at 150,000g for 45 min in a Type 60Ti rotor in an 
ultracentrifuge (Beckman).  Although the majority of recombinant protein exists in the pellet 
after the ultracentrifugation step, sufficient PLC-ε EF-RA2 for subsequent purification is 
recovered in the soluble fraction.  The supernatant is diluted to a final volume of 150 ml with 
lysis buffer and passed through a 5 µM syringe filter to remove any residual debris. 
Metal Chelate Affinity Chromatography 
 Wash a 5-ml HiTrap Chelating HP column (GE Healthcare) with 5 column volumes 
of de-ionized water using a disposable syringe with luer fittings to remove the ethanol in 
which the column is stored.  The column is then charged with Ni2+ by injecting a single 
column volume (5 ml) of 0.1 M NiSO4 with a disposable syringe.  Connect the column to the 
FPLC and equilibrate with the following washes:  5 column volumes of starting buffer 
(starting buffer: lysis buffer minus protease inhibitors), 5 column volumes of elution buffer 
(elution buffer: 20 mM HEPES, pH 8, 300 mM NaCl, 1 M imidazole, 1 mM CaCl2, 1 mM β-
ME , and 10% glycerol), and 5 column volumes of starting buffer.   
The soluble fraction of the whole cell lysate containing approximately 500 µg of 
PLC-ε EF-RA2 per liter of cells is loaded onto the chelating column at a rate of 1 ml/min, 
maintaining a column pressure of < 0.5 mPa.   The column is washed with 10 column 
volumes of starting buffer, followed by 10 column volumes of 50 mM imidazole (5% elution 
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 buffer) to remove proteins nonspecifically bound to the Ni2+ charged resin.  Ultraviolet 
absorbance levels measured at A280 should return to near baseline during the 5% elution 
buffer wash.  Recombinant protein is eluted using a 50 mM to 1 M imidazole gradient (5-
100% elution buffer) over 10 column volumes, collecting 2.5 ml fractions.  A peak of 
absorbance measured at A280 will indicate fractions containing the recombinant protein, 
which is confirmed using Coomassie-stained 7.5 % SDS-PAGE gels (Fig 2).  
Fractions containing recombinant protein are pooled and hexa-histidine-tagged 
tobacco etch virus (TEV) protease is added to the sample to cleave the hexa-histidine tag 
from the PLC-ε fragment.  This mixture is dialyzed overnight against 4 L of dialysis buffer 
(dialysis buffer: 20 mM HEPES, pH 8, 300 mM NaCl, 1 mM CaCl2, and 10% glycerol) at 
4oC to dilute the imidazole used to elute the recombinant protein from the metal chelate 
column.  The amount of TEV protease used should be sufficient to completely cleave the 
hexa-histidine tag from the PLC-ε fragment.   Because individual TEV protease preparations 
have varying specific activities, the amount of enzyme required for complete cleavage is 
determined empirically.  Purification of hexa-histidine-tagged TEV protease was described 
previously [233]. 
A small amount of precipitation may appear in the sample following overnight 
dialysis.  This material is removed by centrifuging the sample for 10 min at 2,000g.  The 
sample is then loaded onto a 1 ml HiTrap Chelating HP column using the FPLC.  The 1 ml 
column is prepared in the same manner as the 5 ml HiTrap Chelating HP column.  A flow 
rate of 0.5 ml/min is used to load the column, keeping the column pressure < 0.5 mPa.  
Although the hexa-histidine tag is cleaved from PLC-ε EF-RA2 by TEV protease, this PLC-ε 
fragment possesses a low affinity for the Ni2+-charged resin and is retained on the column 
56
 during the loading procedure.  The loaded column is washed with 10 column volumes of 
dialysis buffer.  The cleaved PLC-ε fragment is eluted from the column using a 50 mM 
imidazole (5% elution buffer) wash over 10 column volumes, collecting 1 ml fractions.  The 
presence of a non-cleavable hexa-histidine tag on TEV protease results in retention of this 
enzyme by the column during the elution of PLC-ε.  However, the TEV can be eluted with a 
5 column volume, 50 mM to 1 M imidazole (5-100% elution buffer) gradient.  Other 
nonspecific proteins also will be eluted over this range.  The presence of the recombinant 
proteins is confirmed using Coomassie-stained SDS-PAGE (Fig 2).                           
Sephacryl S-300 Gel-Filtration Chromatography 
 Fractions from the second metal chelate affinity column purification step containing 
recombinant PLC-ε EF-RA2 are pooled and applied in a volume of 10 ml to a HiPrep 26/60 
Sephacryl S-300 High Resolution column (26 x 600 mm, 320 ml bed volume) (GE 
Healthcare) equilibrated with buffer A (buffer A: 20 mM HEPES, pH 8, 150 mM NaCl, 1 
mM CaCl2, 1 mM DTT, and 5% glycerol).   This step is performed to ensure the recombinant 
PLC-ε EF-RA2 is monodispersed and not aggregated, however, this step does not 
significantly increase the purity of the sample.  A flow rate of 1 ml/min is used to elute 
proteins and 5 ml fractions are collected starting at injection of the sample.  The elution 
volume (Ve) of the purified PLC is approximately 162 ml as determined by a peak of protein 
absorbance measured at A280, which is verified with Commassie-stained SDS-PAGE gels 
(Fig 2).  These results indicate that PLC-ε EF-RA2 exists as a 117 kDa monomer relative to 
protein standards used to calibrate the S-300 column.  Fractions containing the recombinant 
protein are pooled and concentrated using a 50,000 MWCO PES centrifugal filtering device 
(Vivascience) to a concentration of 1-2 mg/ml.  Aliquots of 25-50 µl are snap frozen and 
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 stored at -80oC.   Repeated freeze-thaw or freezing of diluted samples should be avoided as 
the protein may lose enzyme activity.  Under optimum conditions, the purification process 
should take no more than 72 hr between cell lysis and the freezing of aliquots.  Typical yields 
of near homogeneous, monodispersed 117 kDa PLC-ε EF-RA2 are 1-2 mg per 4 L of 
baculovirus-infected High Five cells. 
Prenylated RhoA Purification 
Cell Infection and Membrane Protein Extraction 
 One liter of High Five cells (~2.0 x 106 cells/ml) are infected with baculovirus 
encoding hexa-histidine-tagged RhoA at an MOI of 1.  Cells are harvested by low speed 
centrifugation (1,000g for 15 min in J6 swinging bucket centrifuge, Beckman) approximately 
forty-eight hours after infection.  The cell pellet is resuspended in 25 ml of ice-cold lysis 
buffer (lysis buffer: 20 mM HEPES, pH 8, 150 mM NaCl, 5 mM MgCl2, 1 mM β-ME, 5% 
glycerol, plus one EDTA-free complete protease inhibitor tablet (Roche)) and lysed using an 
EmulsiFlex C5 cell homogenizer (Avestin).  All subsequent steps are carried out at 4oC.  The 
cell lysate is cleared of intact cells and nuclei by low-speed centrifugation (500g, 15 min, J6 
Beckman centrifuge).  Membranes containing prenylated RhoA are harvest by centrifugation 
of the slow speed supernatant at 150,000g for 45 min. 
 The pelleted membranes are resuspended in 20 ml of extraction buffer (extraction 
buffer: 20 mM HEPES, pH 8,150 mM NaCl, 5 mM MgCl2, 1 mM β-ME, 5% glycerol, 1% 
sodium cholate, and one EDTA-free complete protease inhibitor tablet) and homogenized 
using approximately 20 strokes with a glass/glass dounce homogenizer.  The protein 
concentration of the sample is determined using a Bradford assay, and the sample is diluted 
to a final protein concentration of 5 mg of protein/ml in extraction buffer.  Membrane 
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 proteins are extracted by continuous stirring of the resuspended membrane/detergent mixture 
at 4oC for 1 hr.  Solubilized membrane proteins are recovered by ultracentrifugation of the 
detergent extracted membranes at 100,000g in a Type 60Ti rotor for 1 hr.  The clarified 
supernatant is diluted 3-fold in lysis buffer to achieve a final sodium cholate concentration of 
approximately 0.3%.  Dilution of the detergent sample is important since sodium cholate is 
an ionic detergent and may interfere with protein binding to the Ni2+ charged resin. 
Metal Chelate Affinity Chromatography 
 A 1 ml HiTrap Chelating HP column is prepared as previously described.  Using an 
FPLC, the diluted supernatant containing recombinant RhoA is loaded onto the column at a 
rate of 0.5 ml/min, maintaining a column pressure of < 0.5 mPa.  The column is washed with 
subsequent steps of 10 column volumes of buffer A (buffer A: 20 mM HEPES, pH 8, 150 
mM NaCl, 5 mM MgCl2, 1 mM β-ME, 0.3% sodium cholate, and 5% glycerol), and 10 
column volumes of 5% buffer B (buffer B: buffer A + 1 M imidazole).  Recombinant RhoA 
is eluted using a 50 to 750 mM imidazole gradient (5-75% buffer B) over 20 column 
volumes, collecting 1 ml fractions over the gradient.  Absorbance measured at A280 is used to 
identify fractions containing recombinant protein, and the precence of RhoA is verified using 
12.5% SDS-PAGE Coomassie-stained gels.  Fractions containing the recombinant RhoA are 
pooled and concentrated using a 10,000 MWCO PES centrifugal filtering device 
(Vivascience).    
The concentration of RhoA is determined by replicating the reconstitution assay 
conditions described below in the presence of [35S]GTPγS.  Briefly, approximately 50 
pmoles (estimated from Coomassie-stained SDS-PAGE gels) was reconstituted with 
PE:PtdIns(4,5)P2-containing vesicles in a final volume of 60 µl (see below for buffer 
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 conditions).  The assay includes a 10-fold molar excess of unlabeled GTPγS and 
approximately 100,000 cpm/assay of [35S]GTPγS.  The reaction is incubated at 25oC for 30 
min, allowing the intrinsic exchange of GTPγS for GDP on RhoA, and terminated by the 
addition of 4 ml of stop buffer (stop buffer: 20 mM HEPES, pH 8, 120 mM NaCl, and 25 
mM MgCl2).  The amount of [35S]GTPγS bound RhoA is quantified by filtering samples over 
0.45 µM nitrocellulose filters and liquid scintillation counting of the nitrocellulose 
membranes.   
Phospholipase C assay 
Prepare phospholipid vesicles by combining 30 nmoles/assay L-α-
phosphatidylethanolamine (PE), 3 nmoles/assay PtdIns(4,5)P2, and ~10,000 cpm/assay 
[3H]PtdIns(4,5)P2, in a 12 x 75 mm glass borosilicate tube and drying the lipids under a 
constant stream of nitrogen.  [3H]PtdIns(4,5)P2 is isolated from [3H]-inositol labeled turkey 
erythrocytes as previously described [103] or obtained from commercial sources.  The dried 
lipids are resuspended in 20 µl of 20 mM HEPES, pH 7.4, per assay, and the mixture is probe-
sonicated with approximately five 10 sec pulses.    Once a homogeneous mixture of lipids is 
observed the solution is vortexed and placed on ice.   
Assays are performed in a final volume of 60 µl in 12x75 mm conical polypropylene 
tubes.  Reaction mixtures are prepared in an ice water bath and each assay includes: 1) 10 µl 
of 6X assay buffer (6X assay buffer: 120 mM HEPES, pH 7.4, 420 mM KCl, 12 mM DTT, 
18 mM EGTA, and 17.1 mM CaCl2 (this concentration of EGTA and CaCl2 will yield a final 
free calcium concentration of 1 µM)); 2) 20 µl of phospholipid vesicles giving 30 
nmoles/assay (500 µM) of PE and 3 nmoles/assay (50 µM) PtdIns(4,5)P2; 3) 10 µl of 60 µM 
GDP or GTPγS; 4) 9 µl of 1 mg/ml fatty acid free bovine serum albumin (FAF-BSA); and 5) 
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 10 µl of purified RhoA diluted in buffer A from the FPLC purification.  The tubes are 
vortexed and incubated at 25oC for 20 min to allow GDP or GTPγS to bind to RhoA.  
Reactions are placed on ice and cooled to 4oC prior to the addition of PLC enzyme.   
The amount of PLC enzyme used is determined empirically since different purified 
fractions potentially exhibit varying specific activities.  If 10,000 cpm of PtdIns(4,5)P2 is 
used per assay, the amount of hydrolysis observed by PLC-ε in the absence of G protein 
should be approximately 100-200 cpm above background (usually ~ 50 cpm).  Under any 
given condition, the total number of counts hydrolyzed should not exceed 30% of the starting 
[3H]PtdIns(4,5)P2.  Given the specific activity of the purified fragment, 1-2 ng of purified 
protein usually is sufficient to achieve the desired levels of enzyme activity.  PLC-ε is diluted 
to 1 ng/µl in 1 mg/ml FAF-BSA, and the assay is initiated by the addition of 1 µl of enzyme 
to each tube, which are then vortexed, placed in a 25oC water bath, and incubated for 10 min.  
Final assay conditions are 500 µM PE, 50 µM PtdIns(4,5)P2, 20 mM HEPES, pH 7.4, 70 mM 
KCl, 2 mM DTT, 3 mM EGTA, 2.85 mM CaCl2, 0.16 mg/ml FAF-BSA, and 0.05% sodium 
cholate (final sodium cholate concentration is below the critical micelle concentration for 
sodium cholate).  
The reaction is terminated by the addition of 200 µl of ice cold 10% trichloroacetic 
acid and 100 µl of 10 mg/ml FAF-BSA, which will precipitate proteins and non-hydrolyzed 
lipids.  The tubes are vortexed and centrifuged for 10 min at 3,000g in a J6 swinging bucket 
centrifuge at 4oC.  This step separates the soluble [3H]Ins(1,4,5)P3 cleavage product from 
uncleaved [3H]PtdIns(4,5)P2.  [3H]Ins(1,4,5)P2 is quantified by liquid scintillation counting of 
the reaction supernatant.   
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 The specific activity of the phospholipid substrate in cpm/mol is determined by 
dividing the total cpm of [3H]PtdIns(4,5)P2 used per assay by the total number of moles of 
nonradioactive PtdIns(4,5)P2 used per assay (labeled substrate is not included in the total 
pmol of PtdIns(4,5)P2 since there is a substantial molar excess of unlabeled substrate).  A 
concentration of 50 µM PtdIns(4,5)P2 in a final assay volume of 60 µl gives 3,000 pmoles of 
substrate per assay.  The specific activity is approximately 3.3 cpm/pmol  if 10,000 cpm of 
[3H]PtdIns(4,5)P2 is used per assay.  Dividing this number by the assay duration in minutes 
will give a final value of pmol/min.  
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Figure 2.1.  Purification of PLC-ε EF-RA2 with metal chelate and size exclusion 
chromatography.  A,  above, the left-hand y axis and solid line indicate mAU (A280) and the 
right-hand y axis and hatched line indicate the percentage of elution buffer (1 M imidazole).  
The absorbance peak at 5% elution buffer corresponds to the cleaved PLC-ε EF-RA2 
fragment and the second absorbance peak indicates the elution of hexa-histidine-tagged TEV 
protease and other non-specific proteins.  Below, a Coomassie-stained SDS-PAGE gel 
showing the uncleaved, pooled fractions from the initial metal chelate elution (Pre), TEV 
protease cleaved PLC-ε EF-RA2 (Post) at a lower molecular weight, and elution of 1 ml 
fractions of cleaved PLC-ε from the second metal chelate column at 50 mM imidazole (5% 
elution buffer) over a range of 10 ml.  Note the presence of TEV protease as a band at ~25 
kDa in the post-cleavage lane.  B, above, elution profile of PLC-ε EF-RA2 after injection 
onto an S-300 size exclusion column measuring ultraviolet absorbance (A280) versus volume 
(ml).  Protein standards were used to calibrate the S-300 column (inset).  Below, a load 
sample (L) and samples of 5 ml fractions containing the monomeric PLC-ε EF-RA2 fragment 
eluted from the S-300 column is shown on a Coomassie-stained SDS-PAGE gel.  
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 CHAPTER 3 
 
RHOA ACTIVATES PURIFED PHOSPHOLIPASE C-EPSILON BY A GUANINE 
NUCLEOTIDE-DEPENDENT MECHANISM 
 
3.1 Abstract 
 Phospholipase C-epsilon (PLC-ε) is a recently identified PLC isoform activated by 
subunits of heterotrimeric G proteins (Gα12, Gα13, and Gβγ), as well as by the low molecular 
weight GTPases, Rho and Ras.  To define the enzymatic activity and substrate specificity of 
PLC-ε, as well as its potential direct activation by Rho-family GTPases, a major fragment of 
PLC-ε encompassing the catalytic core (EF-hand repeats through the tandem RA domains; 
~118 kDa) was purified to near homogeneity and assayed after reconstitution under various 
conditions.  Similar to the enzymatic profiles of previously purified PLC-β isozymes, the 
purified fragment of PLC-ε maximally hydrolyzed PtdIns(4)P at a rate of approximately 10 
µmol per milligram protein per minute, exhibited phospholipase activity dependent upon the 
concentration of free calcium, and favored PtdIns(4,5)P2 as substrate relative to other 
phosphoinositides.  Furthermore, in mixed detergent phospholipid micelles, RhoA stimulated 
the phospholipase activity of the PLC-ε fragment in both a concentration-dependent and 
GTPγS-dependent manner.  This activation was abolished by deletion of a unique ~65 amino 
acid insert within the catalytic core of PLC-ε.  Although Rac1 activated purified PLC-β2 in a 
guanine nucleotide-dependent manner, Rac1 failed to promote guanine nucleotide-dependent 
activation of purified PLC-ε.  These results indicate that PLC-ε is a direct downstream 
 effector for RhoA and that RhoA-dependent activation of PLC-ε is dependent on a unique 
insert within the catalytic core of the phospholipase. 
3.2  Introduction 
Phospholipase C (PLC) isozymes respond to a variety of extracellular signaling 
molecules to stimulate hydrolysis of PtdIns(4,5)P2 into the second messengers Ins(1,4,5)P3 
and diacylglycerol [48].  The generation of these two second messengers triggers the release 
of intracellular Ca2+ and stimulation of protein kinase C isozymes, respectively.  Five 
different isoforms of PLC have been identified, each with distinct mechanisms of activation.  
The PLC-β isozymes are directly activated by heterotrimeric G protein α subunits of the Gq 
family [101-103] and by Gβγ subunits [104-106], and were shown more recently to be 
activated by the small GTPase Rac [17;109;110;234].  Activation of receptor and cytosolic 
tyrosine kinases promotes activation of PLC-γ via phosphorylation and translocation 
[56;112;113].  The mechanisms by which extracellular stimuli regulate PLC-δ [94;235] and 
the recently identified PLC-ζ [119;236] are less well understood, although both are believed 
to require the mobilization of Ca2+. 
 The fifth family member of PLC isozymes, PLC-ε, initially was identified in C. 
elegans as a Ras-binding protein [127]. Mammalian PLC-ε subsequently was identified as a 
phospholipase C isozyme containing multiple Ras interaction domains [129;130;133] 
including a CDC25 homology domain in the amino terminus and tandem Ras-associating 
(RA) domains at the carboxyl terminus.  Co-expression of GTPase deficient, constitutively 
active Ras mutants with PLC-ε results in accumulation of inositol phosphates in COS-7 cells 
[130].  Transient coexpression with Gα12, Gα13 [129;131], or Gβγ [131] also promotes 
phospholipase activity of PLC-ε.  More recently, a screen of Rho-family GTPases revealed a 
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 marked activation of PLC-ε when coexpressed with RhoA, RhoB, or RhoC, but not with Rac 
or Cdc42 [142].  This activation was dependent upon a unique ~65 residue insert within the 
Y box of the catalytic TIM-barrel of PLC-ε and co-precipitation studies indicated an 
interaction between PLC-ε and RhoA.  Although these results suggested that PLC-ε is a 
direct, downstream effector of Rho GTPases, other interpretations are also consistent with the 
data.    
To provide incontrovertible evidence for direct activation of PLC-ε by GTP-bound Rho 
GTPases, we have overexpressed and purified a large fragment of the phospholipase (PLC-ε 
EF-RA2; ~118 kDa) and present here the enzymatic characterization of this fragment 
reconstituted with phospholipids and GTPases.  Relative to previously purified PLC 
isozymes, purified PLC-ε EF-RA2 exhibited similar specific phospholipase activity and 
phosphoinositide substrate preferences.  Moreover, our analyses illustrate direct, guanine 
nucleotide-dependent activation of PLC-ε by RhoA and further implicate the catalytic core of 
PLC-ε as the effector region necessary for RhoA-stimulated phospholipase activity.   
3.3  Materials and Methods 
Materials 
The open reading frame of rat PLC-ε was a kind gift from Grant Kelley, State 
University of New York, Syracuse, NY.  A PLC-ε specific antibody was generated by 
BioSource against a predicted exposed sequence (aa 1523-1540; 
LKAHQTPVDILKQKAHQL) directly C-terminal to the X box of the catalytic core. [3H]-
labeled phosphoinositide substrates were prepared from [3H]inositol-labeled turkey 
erythrocytes as previously described [103].  His6-tagged TEV protease was purified as 
previously described [233]. 
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 Purification of PLC-ε EF-RA2 
 A fragment of rPLC-ε encompassing approximately half the EF-hand repeats through 
the second RA domain (amino  acids 1258 through 2215) was amplified from full length 
rPLC-ε by PCR and subcloned into NcoI/XhoI-digested pFastBacHT, which incorporates a 
His6-tag and tobacco etch virus (TEV) protease site at the amino terminus of the expressed 
enzyme.  Baculovirus encoding PLC-ε EF-RA2 was generated using the Bac-to-Bac method 
(Invitrogen).  HighFive insect cells at a density of ~2.0 x 106 cells/ml were infected with 
virus encoding PLC-ε EF-RA2 at a multiplicity of infection of 1.0.  After forty-eight hours of 
incubation at 27 oC, cells were harvested by low speed centrifugation and resuspended in 100 
ml of buffer A (20 mM HEPES, pH 8.0, 300 mM NaCl, 1 mM CaCl2, and 10% glycerol) 
including 2 EDTA-free Complete protease inhibitor tablets (Roche Applied Biosciences).  
Cells were lysed using an EmulsiFlex C5 cell homogenizer (Avestin) and the lysate was 
centrifuged at 100,000g for 45 min.  The clarified supernatant was diluted to a final volume 
of 150 ml and loaded onto a 5-ml HighTrap metal chelate column (Amerhsam Biosciences) 
charged with Ni2+.  Purification steps included a 10 column volume buffer A wash,  a 10 
column volume, 3% buffer B wash (buffer A + 1M imidazole), and recombinant protein was 
eluted with 10 column volumes of 40% buffer B collected in 5 ml fractions.  Fractions 
containing the recombinant protein were dialyzed overnight against buffer A in the presence 
of His6-tagged TEV protease to remove the His6-tag from PLC-ε EF-RA2.  The cleaved 
protein was subjected to a second passage over a Ni2+-charged metal chelate column and 
eluted with 5 mM imidazole as a final purification step.  Fractions containing the purified 
protein were pooled and concentrated using a 50,000 MWCO PES centrifugal filtering 
device (Vivascience).  The final concentration of the recombinant protein was determined by 
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 a Bradford assay relative to bovine serum albumin standards.  Purification of avian PLC-βt  
was previously described [237].  PLC-β2 PH-C2 is a fragment of full length human PLC-β2 
that encompasses amino acid residues 1 through 801 and was purified as previously 
described [17]. 
Purification of FLAG-tagged PLC-ε constructs   
Construction of mammalian expression vectors for PLC-ε EF-Ct and PLC-ε EF-C∆Y 
was previously described [142].  PLC-ε EF-Ct spans amino acids 1198 through 2281 and 
PLC-ε EF-C∆Y spans amino acids 1198 through 2281 but lacks 62 amino acids (residues 
1667-1728) that occur as an approximately 70 amino acid insert that is conserved in all 
orthologues of PLC-ε.  COS-7 cells were seeded on 150 mm dishes at a density of 5.0 x 106 
cells per dish and maintained in high glucose Dulbecco’s modified Eagle’s medium 
containing 10% fetal bovine serum, 100 units/ml penicillin, and 10 µg/ml streptomycin at 37 
oC in an atmosphere of 90% air/10% CO2.  sixty µl of FuGENE 6 (Roche Applied Science) 
transfection reagent was used to transfect 20 µg of each PLC-ε vector construct per dish 
according to manufacturer’s protocol.  The overexpressed recombinant PLC isozymes were 
purified using anti-FLAG M2 affinity gel according to the manufacturer’s protocol (Sigma).  
Briefly, approximately 36 hours after transfection, growth medium was removed from the 
cells and the dishes were rinsed with PBS (10 mM phosphate, 2.7 mM potassium chloride, 
137 mM sodium chloride, pH 7.4).  After aspiration of the PBS, 1 ml of lysis buffer was 
added per dish, and the dishes were incubated for 15 min with shaking.  Cells were scraped 
from dishes, and the lysate was centrifuged at 12,000g for 10 min.  The resultant supernatant 
was subjected to a single gravity flow passage over a 1 ml bed volume of anti-FLAG M2 
affinity gel and washed with 10 bed volumes of TBS (50 mM Tris, pH 7.5, 150 mM NaCl) to 
68
 remove unbound proteins.  Recombinant protein was then collected in six 500 µl elutions 
with 100 µg/ml FLAG peptide in TBS. 
Purification of Small GTPases 
The coding sequences of human monomeric GTPases were amplified by PCR and 
ligated into BamHI/XhoI-digested pFastBacHT.  Baculovirus encoding the Rho-family 
GTPases was produced using the Bac-to-Bac system (Invitrogen).  Recombinant proteins 
were expressed in HighFive insect cells at a density of ~2.0 x 106 cells/ml after infection with 
baculovirus at multiplicity of infection of 1.0.  The cells were harvested after 48 h at 27 oC by 
low speed centrifugation and resuspended in 50 ml buffer A (20 mM HEPES, pH 8.0, 150 
mM NaCl, 1 mM MgCl2, 5% glycerol) with 1 EDTA-free Complete protease inhibitor tablet.  
Membranes of virus-infected cells were harvested by high speed centrifugation at 100,000 x 
g of the cell lysate for 1 h.  Lipidated, membrane-bound small GTPases were solubilized by 
detergent extraction of the harvested membranes in buffer A containing 1% purified sodium 
cholate and 1 EDTA-free Complete protease inhibitor tablet for 1 h at 4 oC.  Solubilized 
membrane proteins were recovered by centrifugation of the extracted membranes at 100,000g 
for 1 h.  The clarified supernatant was diluted with buffer A to achieve a final detergent 
concentration of 0.3% and subsequently loaded onto a HighTrap metal chelate column 
charged with Ni2+ sulfate.  Recombinant protein was collected over an imidazole gradient 
running from zero to 1 M over 20 column volumes.  Fractions containing the recombinant 
GTPase were pooled and concentrated using 10,000 MWCO PES centrifugal filtering device 
(Vivascience).  The concentrations of the individual GTPases were determined by 
quantifying the binding of [35S]GTPγS under the same buffer conditions used for 
reconstitution of the GTPases in phospholipid vesicles described below.   
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 Phospholipase C Assay 
Two different procedures were utilized for measuring phospholipase activity of PLC 
enzymes.  Initial experiments measuring maximum enzymatic activity were carried out in the 
presence of a detergent-substrate mixture.  The second assay employed combined 
phospholipid vesicles with purified GTPases in cholate-containing buffers prior to the 
addition of PLC-ε.  Assays were performed interchangeably using either [3H]PtdIns(4)P or 
[3H]PtdIns(4,5)P2 as substrate as indicated in the figure legends.  
 Maximum enzymatic activity was determined as previously described with minor 
modification [103]. Briefly, PLC isozymes were incubated in final buffer conditions 
including 10 mM HEPES, pH 7.4, 120 mM KCl, 10 mM NaCl, 2 mM EGTA, 5.8 mM 
MgSO4, 0.5% cholate, 100 µM free calcium, 0.16 mg/ml fatty acid free bovine serum 
albumin (FAF-BSA), 100 µM PtdIns(4)P (Avanti Polar Lipids), and ~10,000 cpm/assay 
[3H]PtdIns(4)P in a final volume of 60 µl.  Assays were at 30 oC for 10 min and were 
terminated by addition of 200 µl of 10% trichloroacteic acid and 100 µl of 10 mg/ml FAF-
BSA.  Centrifugation of the reaction mixture separated aqueous [3H]Ins(1,4)P2 from 
precipitated [3H]PtdIns(4)P, and soluble [3H]Ins(1,4)P2 was quantified by liquid scintillation 
counting.   
Most experiments to determine enzyme characteristics and potential regulation by 
small GTPases utilized PE- and PtdIns(4,5)P2-containing lipid vesicles in assays that were 
previously described [238], with minor modifications .  Briefly, recombinant proteins were 
presented in lipid vesicles containing 50 µM PtdIns(4,5)P2, 500 µM 
phosphatidylethanolamine (PE) (Avanti Polar Lipids), and approximately 10,000 cpm 
[3H]PtdIns(4,5)P2 per assay.  Final buffer conditions were 20 mM HEPES, pH 7.4, 70 mM 
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 KCl, 3 mM EGTA, 2 mM dithiothreitol, 0.16 mg/ml FAF-BSA, and 1 µM free Ca2+ in a final 
volume of 60 µl. The concentration of free calcium was calculated using WinMAXC 
software (Stanford University).  All reactions were performed at 25 oC for 10 min after the 
addition of the indicated PLC enzyme.  Experiments designed to determine the substrate 
selectivity of PLC-ε EF-RA2 utilized 1 nmol of each PtdIns, PtdIns(4)P, and PtdIns(4,5)P2, 
along with 30 nmol of PE per assay, changing only the [3H]-labeled phosphoinositide 
substrate for each condition.   
For experiments determining the effects of small GTPases on phospholipase activity, 
10 µl of purified G-protein was reconstituted in phospholipid vesicles, resulting in a final 
cholate concentration of 0.05%.  The small GTPases were loaded with nucleotide by 
incubation with 10 µM GDP or 10 µM GTPγS under assay conditions for 20 min at 25 oC 
prior to the addition of PLC.  Assays were initiated by the addition of PLC enzyme and 
incubations were for 10 min at 25 oC.  Reactions were terminated by the addition of 200 µl of 
10% trichloroacetic acid and 100 µl of mg/ml FAF-BSA.  [3H]Ins(1,4,5)P3 was quantified by 
liquid scintillation counting of the soluble fraction after centrifugation of the reaction 
mixture.   
Vesicle incorporation assays 
To verify whether purified, lipidated GTPases partitioned into phospholipids vesicles, 
sucrose loaded vesicles were prepared at the same ratio of PE and PtdIns(4,5)P2 used in 
reconstitution experiments analyzing PLC enzyme activity.  Briefly, 500 µM PE and 50 µM 
PtdIns(4,5)P2 per assay were combined in a glass borosilicate tube and dried under a stream 
of nitrogen.  The dried lipid film was resuspended in a 0.2 M sucrose, 20 mM HEPES, pH 
7.4 solution and water bath sonicated for 20 min at room temperature.  Approximately 0.2 µg 
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 of bacterially or Sf9 expressed, purified GTPase (prespun at >100,000 x g for 40 min) was 
added to 20 µl of sucrose loaded vesicles.  The proteins lipid mixture was incubated for 30 
min on ice to allow partitioning of proteins into lipid vesicles.  Vesicle were diluted to a final 
volume of 60 µl and final buffer conditions were 20 mM HEPES, pH 7.4, 70 mM KCl, 3 mM 
EGTA, 2 mM dithithreitol, 0.16 mg/ml fatty acid-free bovine serum albumin, 10 µM free 
calcium, 0.08% sodium cholate.  The mixture was spun at >100,000 x g for 45 min to 
sediment sucrose loaded vesicles, the pellet was washed 1X with assay buffer, and the 
mixture was spun again for 30 min.  The resulting supernatant and washed aspirated pellets 
subjected to SDS-PAGE and immunoblotted with anti-6xHis antibody to detect purified 
GTPase.  Control experiments included protein added to 0.2 M sucrose in the absence of 
phospholipid vesicles and the same sedimentation protocol.   
3.4  Results 
Purification of PLC-ε EF-RA2 
 A fragment of PLC-ε (Fig 3.1A) encompassing approximately half the EF-hand 
repeats through second RA domain (amino acids 1258-2215) was purified after 
overexpression from a recombinant baculovirus in HighFive insect cells as described under 
Experimental Procedures.  The soluble fraction of the enzyme bound efficiently to a metal 
chelate column as a first purification step.  After TEV protease cleavage of the affinity tag, a 
second passage over a metal chelate column yielded a nearly homogeneous preparation of the 
recombinant protein (Fig 3.1B).  The purified PLC-ε fragment migrated as a species of 
approximately 118 kDa on SDS-PAGE, as seen by Coomassie staining and immunoblot 
analysis with a PLC-ε specific antibody.  Contaminating proteins observed by Coomassie 
staining were not immunoreactive, suggesting that the impurities were not breakdown 
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 products of the PLC-ε fragment.  Typical yield of purified PLC-ε was 0.5-1.0 mg per liter of 
baculovirus-infected insect cells.  Multiple attempts to purify full-length PLC-ε after insect 
cell expression have yielded insufficient amounts of purified protein.  
PLC activity of PLC-ε EF-RA2 
 The purified PLC-ε fragment exhibited phospholipase C activity in assays utilizing a 
detergent and lipid mixture containing 50 µM [3H]PtdIns(4)P as substrate (Fig 3.1C).  
Enzymatic activity was dependent on the amount of purified phospholipase and was linear 
over a range of concentrations.  The observed enzymatic activity of approximately 10 
µmol/min/mg of protein was similar to that of the widely studied purified avian PLC-βt 
[64;103;105;239].  Subsequent assays were performed utilizing PE- and PtdIns(4,5)P2-
containing vesicles either in the absence of detergent when examining PLC-ε activity alone, 
or in the presence of 0.05% sodium cholate when reconstituting PLC-ε with vesicles 
containing purified small GTPases.  Phosphoinositide hydrolysis was linear for at least ten 
minutes under the conditions of these assays (Fig 3.2A).  Similar to other PLC isozymes, 
enzymatic activity of PLC-ε EF-RA2 was dependent on the concentration of free calcium, 
with an EC50 value of approximately 65 ± 11 nM (n = 3) and maximum activity observed at a 
concentration of approximately 1 µM free Ca2+ (Fig 3.2B).  Kinetic analyses of PLC-ε EF-
RA2 were performed utilizing PE- and PtdIns(4,5)P2-containing vesicles presented at various 
concentrations in the bulk medium (see Experimental Procedures).  These experiments and 
Hofstee analyses revealed a Vmax of ~6.5 µmol/min/mg of protein and a Km value for 
PtdIns(4,5)P2 of approximately 6.0 µM (n = 3) (Fig 3.2C).  The phospholipid substrate 
selectivity of PLC-ε EF-RA2 was determined by using PE- and PtdIns-containing vesicles 
composed of an equal ratio of PtdIns : PtdIns(4)P : PtdIns(4,5)P2.  The recombinant PLC-ε 
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 fragment hydrolyzed phosphoinositides with a rank order of selectivity of PtdIns(4,5)P2 > 
PtdIns(4)P > PtdIns (Fig 3.2D).   
Activation of Recombinant PLC-ε by RhoA 
 Previous studies indicated that the Rho family members, RhoA, RhoB, and RhoC 
induce stimulation of phospholipase activity when transiently coexpressed with PLC-ε in 
COS-7 cells [142]. To determine whether the stimulation of PLC-ε by Rho family GTPases 
is direct, RhoA was expressed from a recombinant baculovirus in insect cells, purified to near 
homogeneity from detergent-extracted membranes, and reconstituted in substrate-containing 
phospholipid vesicles.  As illustrated in the time course assay in Fig 3.2A, recombinant 
RhoA (300 nM) stimulated phospholipase activity of PLC-ε by 2.5 fold in the presence of 
GTPγS, but had no effect in the presence of GDP.  To further assess this phenomenon, RhoA 
was reconstituted over a wide range of concentrations in substrate-containing phospholipid 
vesicles, and PtdIns(4,5)P2 hydrolysis was quantified in the presence of the purified PLC-ε 
fragment (Fig 3.3).  The amount of recombinant PLC-ε used (approximately 2 ng) for 
reconstitution with the GTPases was adjusted to achieve a basal activity of 5-10 pmol/min.  
RhoA caused a 2-3 fold stimulation of PLC-ε in all experiments.  Stimulation was GTPγS-
dependent and half-maximal activation was observed at a concentration of RhoA of 58 ± 18 
nM (n = 4).  The calcium dependence for activation of PLC-ε was not changed in the 
presence of GTPγS-activated RhoA (Fig 3.2B).  GTPγS-dependent activation of PLC-ε was 
not observed with non-lipidated RhoA purified from bacteria suggesting that carboxy-
terminal isoprenylation of RhoA may be required for activation (data not shown).   
The selectivity for activation of PLC-ε by Rho-family GTPases was examined by 
assessing the potential capacity of purified Rac1 to activate PLC-ε following purification of 
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 the lipidated form of the GTPase from baculovirus infected insect cells.  At relatively high 
concentrations (300 nM), Rac1 caused an increase in PLC-ε activity.  However, no guanine 
nucleotide dependence was observed (Fig 3.4).  Lower concentrations of Rac1 had no effect 
on PLC-ε either in the absence or presence of GTPγS (data not shown), and the increased 
activity observed at higher GTPase concentrations may result from contaminating proteins 
that accompany the purification.  Although Rac1 had no effect on PLC-ε activity, this Rho 
family GTPase caused an approximate 2-fold, GTPγS-dependent stimulation of PLC-β2 PH-
C2 (Fig 3.4), consistent with previously published data [17;109;110].   
Activity of the unique Y box insert of PLC-ε 
 Previous transient expression studies in COS-7 cells indicated that a unique amino 
acid insert within the Y box of the catalytic TIM-barrel of PLC-ε not present in other PLC 
isozymes is required for activation of PLC-ε by Rho, Gα12, and Gα13 [142].  To further 
determine the importance of the Y region insert in PLC-ε, two FLAG-tagged fragments of 
PLC-ε were purified after overexpression in COS-7 cells (Fig 3.5, inset).  Both constructs of 
PLC-ε spanned the EF-hand repeats through the C-terminus, with one fragment lacking 62 
amino acids within the Y box (Fig 3.5A).   
 Analyses of the purified PLC-ε fragments in the absence of RhoA indicated that 
removal of the insert within the Y box decreased basal enzymatic activity of the enzyme 
approximately 20-fold.  Therefore, when reconstituted with RhoA-containing phospholipid 
vesicles, the amount of purified PLC-ε fragment added was normalized to give a basal lipase 
activity of approximately 5 pmol/min with each construct.  Under these conditions, 300 nM 
purified RhoA caused an approximate 2-fold stimulation of the PLC-ε EF-Ct fragment, and 
this activation was entirely GTPγS-dependent.  In contrast, no GTPγS-dependent activation 
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 by RhoA was observed with the PLC-ε fragment lacking the 62 amino acid Y box insert (Fig 
3.5B).  These data further support in vivo data suggesting that the Y-insert region is 
necessary for RhoA-dependent activation of PLC-ε. 
3.5  Discussion 
The recent identification of PLC-ε as a downstream effector of Ras and Rho adds a 
new level of complexity to phospholipid signaling involving monomeric GTPases.  In this 
study, we illustrate the direct, GTP-dependent stimulation of PLC-ε in phospholipid vesicles 
reconstituted with purified RhoA.  These data also extend previous in vivo studies in which 
phosphoinositide hydrolysis by PLC-ε promoted by Rho was shown to be dependent on the 
presence of a unique ~65 amino acid sequence within the Y box of the catalytic TIM-barrel 
of PLC-ε.  PLC-ε with this region deleted retained phospholipase activation by Gβγ or H-Ras 
in coexpression experiments in COS-7 cells; however, Rho-, Gα12-, and Gα13-dependent 
activation was not observed [142].   
 A subfamily of RhoGEFs (i.e. p115RhoGEF, LARG, PDZ-RhoGEF) activated by 
Gα12 and Gα13 provides a direct link between stimulation of G-protein coupled receptors and 
the activation of Rho GTPases [143-146].  Because deletion of the unique insert within the Y 
box of PLC-ε causes loss of responsiveness to Rho, Gα12, and Gα13, we hypothesize that 
activation of PLC-ε by Gα12 and Gα13 occurs indirectly by promoting Rho activation.  This 
suggestion is supported by the fact that C3 toxin, which ADP-ribosylates and inactivates 
Rho, prevented activation of PLC-ε by Rho, Gα12, or Gα13, or by agonist activation of a 
lysophosphatidic acid receptor, but does not inhibit the activation of PLC-β isozymes by Gαq 
(M. Hains, M. Wing, T.K. Harden, unpublished data).  Direct activation of PLC-ε by Rho 
does not rule out the possibility of direct activation of PLC-ε by Gα12 or Gα13.  However, our 
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 combined in vivo and in vitro data suggest that Gα12 and Gα13 mostly likely activate PLC-ε 
indirectly via a subfamily of RhoGEFs typified by p115RhoGEF. 
 Although the complete set of determinants within PLC-ε required for interaction with 
Rho have yet to be identified, our current results, combined with previous in vivo data [142], 
have unambiguously identified a region within the catalytic core of PLC-ε as necessary for 
the direct stimulation of the phospholipase activity of PLC-ε by GTP-bound Rho.  Sequence 
analyses of the catalytic regions of PLC-ε have not revealed obvious regions of homology to 
other known Rho-binding domains [211].  In a similar vein, the PH domain of PLC-β2 binds 
GTP-activated Rac [17].  However, the current experiments directly illustrate that the PH 
domain of PLC-ε is not required for activation by RhoA.  These results suggest that eventual 
structural determination of the interface will define a novel mode of effector modulation by 
Rho GTPases.   
The mechanisms whereby Rho-family GTPases activate PLC isozymes remain a 
point of conjecture.  Our unpublished studies suggest that prenylation of RhoA is required for 
stimulation of PLC-ε since soluble bacterial RhoA failed to activate PLC-ε.  GTP-dependent 
binding of the lipidated GTPase to PLC isozymes may promote phospholipase activity by 
causing translocation of the lipase to the phospholipid bilayer.  However, a more active role 
of GTPases may involve conformational changes in PLC isozymes that enhance 
phospholipase activity.  Perhaps the strongest case for GTPase-stimulated phospholipase 
activity occurs with the Rho-promoted activation of PLC-ε studied here, whereby binding of 
Rho within the catalytic core of PLC-ε is readily envisioned to induce conformational 
changes favorable for lipase activity.  Cooperative mechanisms of Rho-dependent activation 
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 of PLC-ε are also possible, whereby Rho induces the lipase activity of PLC-ε through both 
spatial and conformational regulation of the enzyme. 
 The addition of PLC-ε as a direct effector in Rho-dependent signaling expands the 
role of Ras superfamily proteins in phospholipid signaling and metabolism.  Historically, 
Rho family GTPases have been studied as regulators of actin dynamics, gene transcription, 
cell-cycle progression, and cell adhesion [211].  More recently, Rho has been shown to 
increase PtdIns(4,5)P2 levels in cells through activation of phosphatidylinositol 4-phosphate 
5-kinase [240;241] and to negatively regulate diacylglycerol kinase activity [242].  Rho may 
potentiate inositol lipid signaling by increasing PtdIns(4,5)P2 substrate levels and increasing 
PKC activity by inhibition of phosphorylation of DAG.  PLC-ε potentially is involved in 
several signal transduction pathways involving multiple Ras family GTPases.  The data 
reported here illustrate PLC-ε to be an effector for GTP-bound RhoA, and future experiments 
will more completely define the binding regions within PLC-ε and the physiological role 
played by PLC-ε dependent pathways in Rho-activated signaling. 
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Figure 3.1.  Purification and functional activity of PLC-ε EF-RA2.  A, schematic 
representation of full-length PLC-ε (2281 total amino acids; top) and PLC-ε EF-RA2 
(residues 1258 – 2215; bottom).  PLC-ε EF-RA2 lacks the amino-terminal cysteine-rich 
(Cys), CDC25, and PH domains while retaining approximately half the EF-hand repeats, as 
well as the catalytic TIM-barrel (X and Y regions), C2 domain, and tandem RA domains.  B, 
PLC-ε EF-RA2 was purified as described under Experimental Procedures and final samples 
of recombinant protein were analyzed by SDS-PAGE using a 4-15% polyacrylamide 
gradient.  Gels were either Coomassie-stained (left) or transferred to nitrocellulose and 
immunoblotted with an antibody specific to the X-Y linker region of PLC-ε (right).  C, the 
specific activity of the purified PLC-ε fragment was measured using [3H]PtdIns(4)P as 
substrate in the presence of 0.5% sodium cholate for 10 minutes at 30 oC (left) and compared 
to the specific activity of purified avian PLC-βt (right). 
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Figure 3.2.  Characterization of the phospholipase activity of PLC-ε EF-RA2.  A, time 
course of PtdIns(4,5)P2 hydrolysis in the presence PLC-ε EF-RA2 (10 ng) was tested either 
in the absence (open squares) or presence of 300 nM inactive (GDP-bound) RhoA (closed 
circles) or activated (GTPγS-bound) RhoA (closed triangles).  B, PLC-ε EF-RA2 was 
incubated with phospholipid vesicles containing [3H]PtdIns(4,5)P2 substrate under varying 
calcium concentrations in the absence of RhoA (open circles) or presence of 300 nM GTPγS-
bound RhoA (closed circles).  C, the lipase activity of PLC-ε EF-RA2 (2 ng) was assayed 
with increasing concentrations of PtdIns(4,5)P2 substrate.  The data shown are the mean ± 
S.E.M. of three separate experiments and inset is a Hofstee plot of the data.  D, the substrate 
selectivity of PLC-ε EF-RA2 was tested by presentation of either [3H]PtdIns (black bars), 
[3H]PtdIns(4)P (dashed bars), or [3H]PtdIns(4,5)P2 (open bars) with equal amounts of each 
cold substrate per assay as described under Experimental Procedures.  Enzyme activity was 
tested with two different concentrations of the purified enzyme.   
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Figure 3.3.  Activation of PLC-ε by RhoA.  Increasing concentrations of recombinant 
RhoA purified from detergent-extracted HighFive insect cell membranes were reconstituted 
in phospholipid vesicles as described in Experimental Procedures.  Assays included PLC-ε 
EF-RA2 in mixed detergent phospholipid micelles containing [3H]PtdIns(4,5)P2.  After a 20 
min pre-incubation of RhoA with either 10 µM GDP (open circles) or 10 µM GTPγS (closed 
circles), PLC-ε  EF-RA2 (1-2 ng) was added and the assay was performed for 10 min at 25 
oC.  Basal activity of PLC-ε EF-RA2 in the absence of RhoA (5-15 pmol/min) was subtracted 
to give the final values.  The results presented are the mean ± S.E.M. of four individual 
experiments.  
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Figure 3.4.  Stimulation of PLC isozymes by small GTPases.  RhoA and Rac1 were 
purified from detergent extracted HighFive insect cell membranes after expression from 
recombinant baculoviruses as described under Experimental Procedures.  Inset, purified 
proteins were resolved by SDS-PAGE and gels were stained with Coomassie blue.  Purified 
PLC-ε EF-RA2 (2 ng) or PLC-β2 PH-C2 (2 ng) were incubated with mixed detergent 
phospholipid micelles reconstituted with 300 nM of each monomeric GTPase in the presence 
of 10 µM GDP or 10 µM GTPγS.  Data are presented as fold increase of activity observed in 
the presence of GTPγS after subtraction of the basal PLC activity.   
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Figure 3.5.  Loss of Rho-dependent regulation in a PLC-ε fragment lacking a conserved 
insert within the Y box.   A, domain architecture of two PLC-ε fragments that span the EF-
hand repeats through the carboxy-terminus.  Both constructs span amino acids 1198 through 
2281; however, PLC-ε EF-C∆Y lacks residues 1667-1728 within the Y box (dark region).  B, 
both PLC-ε fragments were purified as described in Experimental Procedures and analyzed 
by SDS-PAGE using a 4-15% polyacrylamide gradient (inset).  PLC-ε EF-Ct (1 ng) and 
PLC-ε EF- C∆Y (20 ng) were incubated with detergent-lipid vesicles reconstituted with 300 
nM RhoA in the presence of 10 µM GDP or 10 µM GTPγS using [3H]PtdIns(4,5)P2 as 
substrate.  The data are presented as the fold increase in phospholipase activity in the 
presence of GTPγS-bound RhoA over GDP-bound RhoA after subtraction of basal PLC 
activity.   
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Figure 3.6. Association of purified RhoA with sucrose-loaded phospholipids vesicles.  
The ability of purified, lipidated RhoA (High Five) versus soluble (Bacterial) RhoA to 
associated with phospholipid vesicles was tested by addition of proteins to sucrose-loaded 
vesicles (+) compared to proteins added to sucrose in the absence of lipids (-).  Supernatant 
(S) and pelleted lipid fractions (P) were subjected to SDS-PAGE and proteins were 
visualized by western blotting with anti-His antibody.  The input of total protein (L) is shown 
as a reference.  Data is representative of several G proteins (Rac1, RhoA, Rap1A, Rap2B) 
tested under the same conditions. 
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 CHAPTER 4 
DIRECT, INDEPENDENT, AND DUAL REGULATION OF A RHO AND RAS 
REGULATED PHOSPHOLIPASE EFFECTOR 
 
4.1 Abstract 
 Phospholipase C-epsilon (PLC-ε) is an elaborate PLC isoform involved in a diverse 
set of signaling pathways, including pathways downstream of Ras and Rho family GTPases.  
To determine whether PLC-ε is regulated directly and dually by Rho and Ras family 
GTPases, we have used a combination of in vivo and in vitro assays to quantify regulated 
phospholipase activity.  RhoA and H-Ras markedly stimulated inositol phosphate 
accumulation in PLC-ε expressing cells and required distinct regions of interaction to 
regulate enzyme activity.  PLC-ε-dependent inositol phosphate accumulation observed in the 
presence of a single Ras superfamily GTPase was exceeded by coexpression of maximally 
activating amounts of RhoA and H-Ras together in cells expressing PLC-ε.  Purified PLC-ε 
EF-RA2 also displayed increased activity when presented to PtdIns(4,5)P2-containing 
phospholipid vesicles reconstituted with purified, GTPγS-loaded K-Ras or RhoA.  Mutation 
of two critical lysine residues within the second Ras-association domain of PLC-ε prevented 
K-Ras-dependent activation but retained activation by RhoA.  Furthermore, when maximally 
activated by purified RhoA or K-Ras, PLC-ε was further activated by increasing 
concentrations of the complementary GTPase.  Moreover, PLC-ε displays an increased 
sensitivity to K-Ras activation in the presence of a maximally activating concentration of 
RhoA.  These results indicate that PLC-ε is a direct downstream and dual effector of 
 RhoA and Ras GTPases mediated via interactions within distinct regions of the enzyme. 
4.2 Introduction 
 Receptor activation by a variety of hormones, neurotransmitters, growth factors, and 
other extracellular signaling molecules promotes activation of inositol lipid-specific 
phospholipase C (PLC) enzymes to catalyze the hydrolysis of PtdIns(4,5)P2 into 
diacylglycerol and inositol (1,4,5)-trisphosphate [48].  These second messenger molecules 
are responsible for the stimulation of protein kinase C isozymes and the mobilization of 
intracellular Ca2+, respectively [53;54].  The subsequent depletion of cellular PtdIns(4,5)P2 is 
also involved in cell signaling as various structured domains, including some PH, FERM, 
ENTH, and PX domains, specifically bind inositol lipids to promote membrane localization 
and/or regulate functional activity [5;7].  PtdIns(4,5)P2 binding proteins are implicated in 
several cell signaling events including membrane trafficking, changes in the actin 
cytoskeleton, and ion channel and transporter function [7]. 
The six PLC subfamilies (PLC-β, -γ, -δ, -ε, -ζ, and -η) all contain conserved X- and 
Y-boxes, which fold together to form a catalytic triose-phosphate isomerase (TIM) barrel.  
Elaboration of the catalytic core with various protein binding and/or regulatory domains 
gives rise to multiple modes of regulation and different PLC subfamilies.  PLC-β isozymes 
are activated by heterotrimeric Gα subunits of the Gq family [101-103], Gβγ subunits [104-
106], and the small GTPase Rac [17;71;109;110].  The region linking the catalytic X- and Y-
boxes of PLC-γ isoforms encompass a split PH domain, two SH2 domains, and an SH3 
domain, resulting in regulation by tyrosine phosphorylation and translocation to the plasma 
membrane [56;112;113].  More recently, Rac GTPases have been shown to specifically 
activate PLC-γ2, but not PLC-γ1 [116].  Emerging evidence suggests the recently identified 
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 PLC-η is regulated by heterotrimeric Gβγ subunits [123].  The regulation of PLC-δ [94;235] 
and PLC-ζ [119;236] are less well understood, although both are believed to be sensitive to 
lower levels of intracellular calcium compared to other PLC isozymes. 
The sixth family member of PLC isozymes, PLC-ε, was initially identified in C. 
elegans as a Ras-binding protein [127].  Subsequent cloning of the mammalian homolog of 
PLC-ε confirmed the presence of conserved Ras-interacting domains, including tandem 
carboxy-terminal Ras-associating (RA) domains and an amino-terminal CDC25 homology 
domain [129;130;133].  Coexpression of constitutively active Ras-family GTPases, including 
Ras and Rap family members, with PLC-ε results in an increased accumulation of inositol 
phosphates in COS-7 cells [130;140;142].  In vitro studies with various Ras proteins and 
PLC-ε has yielded conflicting results regarding the possibility of direct regulation of PLC-ε 
by Ras family GTPases [130;133;141].   In addition to Ras regulation of PLC-ε activity, 
coexpression of PLC-ε with Gα12, Gα13 [129;131], or Gβγ [131] also promotes increased 
phospholipase activity in COS-7 cells.  Finally, we have identified PLC-ε as a direct effector 
of Rho family GTPases, specifically RhoA, RhoB, and RhoC [142;231].  The combination of 
in vivo coexpression of PLC-ε with Rho GTPases and in vitro reconstitution experiments 
with purified proteins confirmed PLC-ε as a direct downstream effector of Rho GTPases.   
Direct activation of PLC-ε by Ras superfamily GTPases has not been unambiguously 
substantiated in studies with purified proteins.  The goals of this study were to establish 
incontrovertible evidence regarding the direct regulation of PLC-ε by Rho and Ras family 
GTPases and to show that Rho and Ras interact with distinct regions of PLC-ε to 
independently and dually regulate PLC-ε enzyme activity.  Coexpression of RhoA and Ras 
GTPases with various PLC-ε constructs confirms previous studies suggesting that 
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 independent sites are involved in Rho- versus Ras-mediated enzyme regulation.  
Additionally, coexpression of RhoA and H-Ras resulted in PLC-ε-dependent increases in 
inositol phosphate accumulation that were markedly greater than that observed with 
expression of PLC-ε with either GTPase individually.  To begin an unambiguous evaluation 
of the potential dual regulation of PLC-ε by two different Ras superfamily GTPases, we have 
examined this signaling system using in vitro reconstitution of purified proteins in model 
PtdIns(4,5)P2-containing phospholipid vesicles.  Our in vitro analyses illustrate that RhoA 
and K-Ras individually are sufficient to increase the activity of a purified fragment of PLC-ε 
(PLC-ε EF-RA2) in both a GTPγS- and concentration-dependent manner.  Point mutations 
made at two critical lysine residues in the second RA domain of PLC-ε results in loss of K-
Ras- but not RhoA-dependent enzyme activity and confirm in vivo data suggesting the sites 
of interaction on PLC-ε for RhoA and Ras GTPases are mutually exclusive.  Additionally, 
when PLC-ε is activated by a maximally effective concentration RhoA or K-Ras, the activity 
of PLC-ε is increased further by the addition of increasing concentrations of K-Ras or RhoA, 
respectively.  Moreover, when maximally activated by RhoA, PLC-ε displays an increased 
sensitivity to K-Ras. 
4.3 Materials and Methods  
Materials  
 The open reading frame of rat PLC-ε in pCMV-script was a kind gift from Grant 
Kelley, State University of New York, Syracuse, NY.  Hemagglutinin A-tagged and GTPase 
deficient mutants of Ras-family GTPases were obtained from the Gutherie Institute (Sayre, 
PA).  His6-tagged TEV protease was purified as previously described [233].  
Construction of Mammalian PLC-ε Expression Vectors 
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 PLC-ε fragments were constructed as previously described [142].  Briefly, full-length 
rPLC-ε cDNA was used as a template to PCR amplify the selected regions following 
standard protocols and ligated in-frame into pCMV-myc (Clontech).  Constructs were 
confirmed by sequencing.  The specific constructs used and amino acid ranges are as follows: 
CDC25-Ct, 509-2281; CDC25-RA1, 509-2113; and EF-Ct∆Y, 1198-2281 lacking residues 
1667-1728. 
Transfection of COS-7 Cells and Quantification of Inositol Phosphate Accumulation  
COS-7 cells were maintained in high glucose Dulbecco’s modified Eagle’s medium 
containing 10% fetal bovine serum, 100 units/ml penicillin, and 100 ug/ml streptomycin at 
37oC in an atmosphere of 90% air/10% CO2.  Cells were seeded in 12-well culture dishes at a 
density of ~65,000 cells per well 24 h prior to transfection.  The indicated DNA vectors were 
transfected using FuGENE 6 (Roche Applied Science) transfection reagent according to the 
manfucaturer’s protocol.  The total amount of DNA used per well was 700 ng and included 
empty vector to maintain an equal amount of DNA per well.  Approximately 24 h after 
transfection, the culture medium was changed to inositol-free Dulbecco’s modified Eagle’s 
medium (ICN Biomedicals) containing 1 µCi/well myo-[2-3H(N)]inositol (American 
Radiolabeled Chemicals).  Metabolic labeling was allowed to proceed for 12-18 h.  
Accumulation of [3H]-labeled inositol phosphates was quantifiated following a 60 min 
incubation in the presence the 10 mM LiCl to inhibit inositol monophosphatases.  The 
reaction was stopped by aspiration of the culture medium and subsequent addition of 50 mM 
formic acid followed by neutralization with 150 mM NH4OH.  [3H]-inositol phosphates were 
isolated and quantified using Dowex chromatography as described previously [243]. 
Purification of PLC-ε fragments  
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 PLC-ε EF-RA2 (amino acids 1258-2215) was amplified from full-length rPLC-ε and 
subcloned into NcoI/XhoI-digested pFastBacHT, which incorporates an amino-terminal 
hexahistidine tag and tobacco etch protease site for cleavage of the affinity tag.  Site-directed 
mutagenesis was used to generate PLC-ε EF-RA2 (K>E), a construct with two point 
mutations at lysine residues 2150 and 2152, both mutated to glutamic acid.  Baculoviruses 
encoding each PLC-ε construct were generated using the Bac-to-Bac method per the 
manufacture’s instructions (Invitrogen).  PLC-ε EF-RA2 and PLC-ε EF-RA2 (K>E) were 
purified as described previously with minor modifications [231;244].  HighFive cells were 
grown in 4 liter shaker flasks at 27oC to a density of ~2.0 X 106 cells/ml and infected with 
virus encoding either PLC-ε EF-RA2 or PLC-ε EF-RA2 (K>E) at a multiplicity of infection 
of 1.0.  Cells were harvested 48 h after infection by low speed centrifugation and 
resuspended to a final volume of 150 ml in buffer A (20 mM HEPES, pH 8.0, 300 mM NaCl, 
1 mM CaCl2, 10% glycerol, and EDTA-free Complete protease inhibitor tablets (Roche 
Applied Science)).  The resuspended cells were lysed by passage through an EmulsiFlex C5 
homogenizer (Avestin).  Intact cells and nuclei were removed from the lysate by low speed 
centrifugation at 500 x g for 15 min.  The supernatant from the low-speed centrifugation was 
clarified by centrifugation at 100,000g for 1 h.  The resulting supernatant was diluted to a 
final volume of 150 ml and loaded onto a 5-ml HisTrap metal chelate column (GE 
Healthcare) charged with Ni2+.  The loaded column was washed with 10 column volumes of 
buffer A, followed by a 10 column volume, 3% buffer B wash (buffer A + 1 M imidazole).  
Recombinant protein was eluted using a 3-50% buffer B linear gradient over 20 column 
volumes collecting 5 ml fractions.  Fractions containing recombinant protein were pooled, 
and hexahistidine-tagged TEV protease was added to the sample to cleave the hexahistidine-
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 tag from the PLC-ε fragment.  The sample was dialyzed overnight against buffer A to 
remove the imidazole.  The cleaved PLC-ε fragment was subjected to a second passage over 
a Ni2+-charged 1-ml HisTrap column, and the protein was eluted with buffer containing 5 
mM imidazole, which separates of the cleaved PLC-ε fragment from the hexahistidine-tag 
and TEV protease.  Fractions containing the recombinant protein were pooled and 
concentrated using a 50,000 MWCO PES centrifugal filtering device (Sartorius).  PLC-β2 
PH-C2 (amino acids 1-801) was purified as described previously [71]. 
Purification of Monomeric GTPases 
Full-length human monomeric GTPases were amplified by PCR and ligated into 
BamHI/XhoI-digested pFastBacHT, which incorporates an amino-terminal hexahistidine tag.  
Baculoviruses of each individual GTPase were produced using the Bac-to-Bac system per 
manufacture’s protocol.  HighFive cells at a density of ~2.0 X 106 cells/ml were infected 
with baculovirus at an MOI of ~1.0.  48 h after infection, cells were harvest at 27oC by low 
speed centrifugation and resuspended in a final volume of 100 ml of buffer A (20 mM 
HEPES, pH 8.0, 150 mM NaCl, 1 mM MgCl2, 5% glycerol, 1 mM DTT, one EDTA-free 
Complete protease inhibitor tablet).  Cells were lysed using an Emulsiflex C5 homogenizer.  
Cell lysate was cleared of intact cells and nuclei by low speed centrifugation at 500g for 15 
min.  Membranes of virus-infected cells were harvested from the resulting supernatant by 
high speed centrifugation at 100,000g for 1 h.  Post-translationally modified, membrane 
bound GTPases were extracted from the harvested membranes after resuspension in buffer A 
containing 1% sodium cholate and one EDTA-free Complete protease inhibitor at a final 
protein concentration of 5 mg/ml.  Resuspended membranes were subjected to rapid stirring 
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 for 1 h at 4oC.  Solubilized membrane proteins were separated from the particulate fraction 
by centrifugation at 100,000g for 1 h.   
Ni-NTA agarose (Qiagen) was added to the resulting supernatant and incubated for 1 
h at 4oC.  The resulting slurry mixture was added to a gravity flow column and washed with 
10 CV of buffer A containing 500 mM NaCl.  The column was then equilibrated with buffer 
A containing 10 mM NaCl, and recombinant protein was eluted in 10 CV buffer B (20 mM 
HEPES, pH 8.0, 10 mM NaCl, 1 mM MgCl2, 400 mM imidazole, 5% glycerol, 0.5% sodium 
cholate).  Sample containing the eluted protein was diluted to 50 ml in buffer B and applied 
to a 1 ml HiTrap Q column (GE Healthcare).  The loaded column was washed with 10 CV of 
buffer B and protein was eluted using a linear NaCl gradient from 10 mM to 500 mM over 25 
CV.  Fractions containing the recombinant protein were pooled and applied directly to a 1-ml 
HisTrap column (GE Healthcare) charged with Ni2+.  The loaded column was washed with 
10 column volumes of buffer C (20 mM HEPES, pH 8.0, 150 mM NaCl, 1 mM MgCl2, 0.5% 
sodium cholate, 5% glycerol) and 10 column volumes of 5% buffer D (buffer C + 1 M 
imidazole).  Protein specifically bound to the column was eluted with a 0 to 50% buffer D 
gradient over 20 CV collecting 1 ml fractions.  Fractions containing recombinant GTPase 
were pooled and concentrated using a 10,000 MWCO PES centrifugal filtering device.  All 
steps were completed within one day with no freezing of the sample between column 
purifications.  The concentrations of the individual GTPases were determined by quantifying 
the binding of [35S]GTPγS under identical buffer and assay conditions described below for 
reconstitution of the GTPases with phospholipid vesicles. 
Phospholipase C Reconstitution Assay 
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 Experiments to determine PLC enzyme regulation by G proteins were performed as 
previously described with minor modifications [231;244].  Briefly, phospholipid vesicles 
were created by combining 600 uM PE (Avanti Polar Lipids), 50 uM PtdIns(4,5)P2, and 
~10,000 cpm of [3H]PtdIns(4,5)P2 (Perkin Elmer) per assay into a glass borosilicate tube and 
drying the mixture under a stream of nitrogen.  Vesicles were created by resuspension of the 
dried lipids in 20 mM HEPES, pH 7.4, followed by probe sonication.  Assay were performed 
in a final volume of 60 µl with final buffer conditions containing 20 mM HEPES, pH 7.4, 70 
mM KCl, 3 mM EGTA, 2 mM dithithreitol, 0.16 mg/ml fatty acid-free bovine serum 
albumin, 10 µM free calcium, and 0.08% sodium cholate.  Purified GTPases were diluted 6-
fold into the assay, resulting in a final cholate concentration of 0.03%.  The GTPases were 
loaded with nucleotide in the absence of PLC by incubating the G protein/lipid suspension 
for 30 min at 30oC with 10 µM GDP or 10 µM GTPγS.  Reactions were initiated by the 
addition of purified PLC and incubations were at 30oC for 5-10 min as indicated in the figure 
legends.  Reactions were terminated by the addition of 200 µl of 10% tricholoroacetic acid 
and 100 µl of 10 mg/ml fatty acid-free bovine serum albumin.  Soluble [3H]inositol 
phosphates were quantified by liquid scintillation counting of the soluble fraction after 
centrifugation of the reaction mixture.   
4.4 Results 
Activation of PLC-ε by Small GTPases 
 Our previous studies suggested that Rho and Ras GTPases regulate the activity of 
PLC-ε through specific and separate regions of the enzyme [142].  These observations were 
extended by a series of experiments in COS-7 cells transiently transfected with DNA 
encoding RhoA or H-Ras with various constructs of PLC-ε.  Activity observed with PLC-ε 
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 lacking the amino-terminal region (CDC25-Cterm) was markedly increased by coexpression 
with either RhoA or H-Ras (Fig 4.1B).  Removal of the RA2 domain of PLC-ε (CDC25-
RA1) resulted in an isozyme that was not activated by H-Ras, but retained RhoA-promoted 
inositol phosphate accumulation.  PLC-ε lacking an insertion within the Y-box that is unique 
to PLC-ε isozymes (EF-Ct∆Y) was not activated by coexpression with RhoA; however, 
removal of the Y-box insert did not affect the ability of PLC-ε to be regulated by H-Ras 
[142].  These experiments confirm previously identified regions required for GTPase-
dependent regulation of PLC-ε and suggest that PLC-ε potentially is dually regulated by both 
Rho and Ras GTPases. 
 To assess the ability of PLC-ε to be regulated simultaneously by Rho and Ras 
GTPases, full-length PLC-ε was expressed in COS-7 cells with various amounts of RhoA or 
H-Ras DNA to determine the amount of DNA required for maximal PLC-ε stimulation (data 
not shown).  These maximal activating amounts of RhoA and H-Ras then were transiently 
expressed together with PLC-ε in COS-7 cells.  As illustrated in Fig 4.2, coexpression of 
RhoA and H-Ras together resulted in PLC-ε-dependent inositol phosphate accumulation 
significantly greater than that observed in the presence of either GTPase individually.  
Western blots confirmed that the levels of GTPase or PLC-ε expression from the indicated 
amounts of DNA were not changed by coexpression with various other expression vectors.    
Selective G Protein Regulation of PLC-ε Activity 
 To unequivocally illustrate that GTPases specifically increase the activity of PLC-ε 
via direct protein-protein interactions, various G proteins (i.e. RhoA, K-Ras, Rac1, and Gβγ) 
were overexpressed in insect cells, harvested from detergent extracted membranes, and 
purified to homogeneity as described under “Experimental Procedures.”  K-Ras was used as 
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 the model Ras GTPase in these studies because it was readily purifed in ample amounts as an 
active and lipidated protein.  Purified, lipidated GTPases were reconstituted in 
[3H]PtdIns(4,5)P2 substrate-containing phospholipid vesicles and their capacity to activate 
purified PLC-ε was examined.   Both RhoA (125 nM) and K-Ras (125 nM) markedly 
increased the enzyme activity of purified PLC-ε EF-RA2 and the stimulatory effects of these 
GTPases occurred following preloading of the GTPases with GTPγS, but not with GDP (Fig 
4.3A).  Soluble GTPases purified from bacteria failed to activate PLC isozymes (data not 
shown). 
In contrast to the activation observed with RhoA or K-Ras, purified, GTPγS-loaded 
Rac1 did not increase the activity of PLC-ε.  GTPγS-bound Rac1 did increase the activity of 
purified PLC-β2 PH-C2 (Fig 4.3B), consistent with previously published data [110;231].  
Under the same assay conditions, GTPγS-bound RhoA and K-Ras did not activate purified 
PLC-β2 PH-C2.  A small increase in PLC activity occurred with RhoA and K-Ras, as well as 
Rac1, in the presence of GDP and we attribute this to effects resulting from reconstitution of 
various amounts of protein in the vesicle preparation, often leading to changes in overall 
enzyme activity. 
 Results from our previous studies illustrated increased inositol phosphate 
accumulation in COS-7 cells transiently transfected with Gβγ dimers and PLC-ε [131].  To 
assess if the observed increase in lipase activity is due to a direct interaction between Gβγ 
and PLC-ε, purified Gβ1γ2 was reconstituted in phospholipid vesicles, and inositol lipid 
hydrolysis was measured in the presence of purified PLC-ε EF-RA2 or PLC-β2 PH-C2.  As 
illustrated in Fig 3C, purified, lipidated Gβ1γ2 (200 nM) increased the activity of purified 
PLC-β2 PH-C2 by ~10-fold, but had no effect on PLC-ε EF-RA2 activity.  Various other 
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 concentrations of purified Gβ1γ2 ranging from 1 nM to 500 nM also did not increase the 
activity of purified PLC-ε EF-RA2 (data not shown), suggesting the increased enzyme 
activity observed when PLC-ε is coexpressed with Gβγ dimers in vivo is not due to a direct 
interaction.  Additionally, when Gβ1γ2 was reconstituted with GTPγS-bound RhoA or K-Ras 
in phospholipid vesicles, the activity of purified PLC-ε EF-RA2 was not increased above the 
level observed in the presence of RhoA or K-Ras alone (data not shown). 
Regulation of PLC-ε by RhoA and K-Ras Through Interactions with Distinct Regions  
 Interaction and regulation of PLC-ε with various Ras-family GTPases in intact cells 
is dependent on the presence of the second Ras-associating domain of PLC-ε [130;133;142].  
In contrast, RhoA-dependent regulation of PLC-ε requires only the catalytic core of the 
enzyme and is dependent on the presence of a unique insert within the Y-box of the PLC-ε 
catalytic region [142;231].  To determine whether PLC-ε is directly regulated through 
distinct interactions of the enzyme with RhoA and K-Ras, a double-mutation in the second 
RA2 domain of PLC-ε EF-RA2 (K>E), previously shown by Kelley et al. to inhibit 
activation of PLC-ε by Ras GTPases in vivo, was introduced into the wild-type PLC-ε EF-
RA2 construct [130].  The double mutation in the RA domain of PLC-ε results in a charge 
reversal of both lysine residues, creating a negatively charged surface potential, which 
ostensibly repels the negatively charged potential of Ras family switch regions.  
Additionally, amino acid 2150 was recently shown to form contacts with the switch I region 
of H-Ras [135].  The PLC-ε EF-RA2 (K>E) fragment was purified to homogeneity using the 
same methodology used to purify wild-type PLC-ε EF-RA2. 
Analyses of the purified PLC-ε fragments in the absence of RhoA or K-Ras indicated 
that the double mutation within the second RA domain of PLC-ε EF-RA2 (~3.0 pmol/min/ng 
96
 protein) had little effect on basal phospholipase activity compared to wild-type PLC-ε EF-
RA2 (~4.9 pmol/min/ng protein).  When reconstituted with RhoA or K-Ras, wild-type PLC-ε 
EF-RA2 activity was increased in the presence of RhoA and K-Ras in a GTPγS-dependent 
manner (Fig 4.4).  In contrast, whereas the PLC-ε EF-RA2 double mutant retained 
stimulation by GTPγS-bound RhoA, enzyme activity was not increased by GTPγS-bound K-
Ras over a wide range of concentrations.  These data support the combined in vivo and in 
vitro data suggesting that two distinct sites of interaction exist in PLC-ε for RhoA and K-Ras, 
and that the second RA domain is essential for Ras-dependent activation of PLC-ε.    
Dual Regulation of PLC-ε by RhoA and K-Ras 
 Results from the previous experiment confirm that PLC-ε is regulated by RhoA and 
K-Ras in a GTPγS-dependent manner through interactions with distinct regions of PLC-ε.  
To test whether a combination of the two GTPases increases the activity of PLC-ε above that 
observed with a single GTPase, RhoA and K-Ras were co-reconstituted in the same 
phospholipid vesicle preparation, and the phospholipase activity of purified PLC-ε EF-RA2 
was assessed.  At maximally activating concentrations of either RhoA or H-Ras (300 nM) 
preloaded with GTPγS, the rate of substrate hydrolysis of wild-type PLC-ε ER-RA2 
increased approximately 2.5-fold over that observed with PLC-ε alone (Fig 4.5, Table 4.1).  
When maximally activating concentrations of RhoA (300 nM) and K-Ras (300 nM) were 
combined in the same vesicles, the enzymatic rate of PLC-ε EF-RA2 was approximately 
additive with the stimulation observed with RhoA or K-Ras individually (Fig 4.5).  Inositol 
lipid hydrolysis was linear for at least 8 min under the assay conditions utilized.   
 To further assess the regulation of PLC-ε by both RhoA and K-Ras, each individual 
GTPase was reconstituted over a wide range of concentrations in phospholipid vesicles with 
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 wild-type PLC-ε EF-RA2 (Fig 4.6).  The enzyme activity of purified PLC-ε was increased in 
a concentration-dependent manner by GTPγS-bound RhoA or K-Ras.  At maximal 
concentration of either RhoA or H-Ras (300 nM), the rate of substrate hydrolysis of wild-
type PLC-ε ER-RA2 increased by approximately 2.5-3 fold (Fig 4.6, Table 4.1).  Under these 
assay conditions, RhoA (~20 nM) and K-Ras (~15 nM) exhibited similar EC50 values for 
activation of PLC-ε EF-RA2.  Additionally, when the same concentration range of RhoA was 
examined in the presence of a maximally activating concentration of K-Ras (300 nM), the 
resulting activity was essentially additive, and little or no change in the observed EC50 of 
RhoA was observed (Fig 4.6A).  Concentration-dependent activation of PLC-ε by K-Ras was 
observed in the presence of a maximally activating concentration of RhoA (300 nM).  
However, in contrast to the lack of effect of K-Ras on the RhoA activation curve, the 
presence of 300 nM RhoA resulted in an approximately three fold decrease in the EC50 
observed for K-Ras (Table 4.1).  Thus, dual, independent, and additive activation of PLC-ε 
occurs in response to purified RhoA and K-Ras.  Additionally, maximal activation of the 
isozyme by RhoA results in an increase in sensitivity to activation by K-Ras. 
4.5 Discussion 
 The presence of tandem carboxy-terminal RA domains has implicated PLC-ε as a 
potential downstream efffector of activated Ras GTPases; however, in vitro studies provide 
conflicting results regarding the ability of Ras family proteins to directly regulate PLC-ε 
enzyme activity [130;133;135].  In this study, we demonstrate the direct, GTPγS- and 
concentration-dependent stimulation of purified PLC-ε in phospholipid vesicles reconstituted 
with purified, lipidated K-Ras.  These data also confirm previous studies suggesting 
association with the RA2 domain is required for Ras-regulated activity, since mutation of two 
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 critical lysine residues within this region results in the loss of Ras-promoted enzyme activity.  
However, mutations within the second RA domain of PLC-ε did not affect Rho-promoted 
activation in vivo or in vitro.  These data substantiate our in vivo coexpression experiments 
implicating PLC-ε as a direct downstream effector of Rho and Ras GTPases through 
interactions with distinct regions of PLC-ε. 
 Determination of the individual regions of PLC-ε required for Rho and Ras family 
regulation, as well as apparent additive stimulation of PLC-ε activity upon coexpression with 
Rho and Ras in COS-7 cells, suggested potential dual regulation of PLC-ε by Rho and Ras 
family GTPases.  Indeed, when purified PLC-ε EF-RA2 was added to phospholipid vesicles 
reconstituted with maximally activating concentrations of RhoA and K-Ras, the 
phospholipase activity of PLC-ε EF-RA2 exceeded that observed with either GTPase 
individually.  Additionally, when maximally activated by RhoA, PLC-ε displayed increased 
sensitivity to K-Ras activation, with an approximately three-fold leftward shift in the 
apparent EC50 compared to the activation observed with K-Ras alone.  These data suggest 
that K-Ras and RhoA ultimately regulate PLC-ε activity by different mechanisms.  Herein, 
we have identified PLC-ε as a unique enzyme that is regulated dually by two separate Ras 
superfamily GTPases through interactions with distinct regions of the effector protein.  
 The observed additive activity of PLC-ε by Rho and Ras family GTPases suggests the 
binding of both GTPases does not cause in a transfer of energy resulting in a conformational 
change within the active site of the enzyme.  The relatively large size of PLC-ε allows the 
enzyme to bind various GTPases through distinct regions while the binding of one GTPases 
would not affect the binding of a complimentary GTPase at a more distant site.  However, 
although the activity of both GTPases together is additive, our data suggests that activation of 
99
 PLC-ε by RhoA increases the sensitivity to K-Ras activation.  These data would suggest that 
RhoA binding to PLC-ε either orients the enzyme at the membrane in a favorable position for 
K-Ras to bind the RA2 domain of PLC-ε; or that RhoA binding relieves inhibition of the RA 
domains.  Our hypothesis is that the binding of Rho or Ras GTPases to PLC-ε are mutually 
exclusive events and that the binding of PLC-ε to membrane associated GTPases results in an 
increased ability of the enzyme to associate with lipid membranes.  Under these conditions, 
the binding of a single GTPases would reduce the ability of PLC-ε to dissociate from the 
membrane, thereby lowering the off rate between the enzyme and membrane.  Upon binding 
to both Rho and Ras GTPases, the off rate for the PLC-ε/membrane event is reduced even 
further, essentially locking the enzyme at the membrane and increasing the activity observed 
with either GTPase alone.   
 Other mechanisms of dual regulation of PLC-ε by multiple GTPases are possible; 
however, our kinetic data suggests the binding events are mutually exclusive events.  If the 
activity of PLC-e were greater than additive in the presence of both GTPases, we would 
hypothesize that the binding of both GTPases would result in a combined effort to activate 
the enzyme.  For instance, the binding of Rho and Ras to a similar region near the catalytic 
site could move the X-Y linker region of the enzyme, thereby relieving the autoinhibition and 
ultimately leading to synergistic activation.  Conversely, the binding of both GTPases could 
reduce the activity observed with a single GTPase, which would suggest a either a similar 
binding site for both GTPases or that the binding of either GTPase would reduce the binding 
of the other GTPase.  Finally, it would also be possible for the activity of PLC-e to remain at 
the level of either GTPase individually in the presence of both GTPases.  This scenario 
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 would suggest a shared binding site for both Rho and Ras GTPases, or that the off rate for the 
enzyme/membrane association can not be increased in the presence of both GTPases.  
 Many signaling cascades emanate from activation of the over 150 Ras superfamily 
GTPases.  However, dual regulation of a single protein by RhoA and Ras GTPases to our 
knowledge does not exist.  Our current understanding of PLC-ε regulation places the enzyme 
at a point of convergence for several signaling pathways downstream of both heterotrimeric 
and multiple Ras superfamily GTPases.  However, the spatial and temporal regulation of 
PLC-ε by multiple GTPase signaling pathways has yet to be delineated. Other well 
characterized effectors of multiple Ras superfamily GTPases, also involved in phospholipid 
metabolism, are class I PI3Ks.  Ras and Rac GTPases interact with distinct subunits of PI3Ks 
to regulate functional activity; Ras GTPases binding to the p110 subunit, and Rac GTPases 
binding to the p85 subunit of PI3Ks [182;245;246].   
 The mechanisms by which Ras superfamily GTPases activate PLC-ε have yet to be 
elucidated.  Our studies suggest that lipidation of GTPases is essential for the activation of 
PLC isozymes in reconstitution assays because bacterially expressed soluble GTPases failed 
to activate PLC-ε.  The requirement for lipidation suggests activated Ras superfamily 
GTPases recruit PLC-ε to phospholipid membrane surfaces resulting in increased enzyme 
activity.  Other potential mechanisms of PLC-ε regulation by Ras superfamily GTPases 
involve the initiation of conformational changes within the enzyme upon binding of activated 
GTPases.  Bunney and colleagues proposed a mechanism of PLC-ε autoinhibition whereby 
the RA domains fold back onto the catalytic regions of the enzyme, which is relieved upon 
binding to Ras and translocation to the plasma membrane [135].  Additionally, several lines 
of evidence have implicated the highly variable X-Y linker region in autoinhibition of PLC 
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 enzymes by occluding the active site of several isozymes [60;70;71].  Our identification of a 
unique sequence in the Y-box of PLC-ε that is required for RhoA-promoted PLC-ε activity 
suggests the potential for Rho GTPases to relieve this autoinhibition by binding PLC-ε 
proximal to the X-Y linker region.  
 Mechanistic insights into the regulation of PLC-ε by Ras superfamily GTPases will 
be aided by structural determination of PLC-ε in complex with G protein activators.  The 
recent solved crystal structure of PLC-β2 in complex with Rac1 revealed direct binding of 
activated Rac1 to the PH domain of PLC-β2 [71].  Comparing the structure of PLC-β2 alone 
to PLC-β2 bound to Rac1 suggests little or no change in the conformation of the catalytic 
region of PLC-β2.  Thus, binding to Rac1 results in membrane localization and orients the 
catalytic region of PLC-β2 in a favorable position to facilitate increased substrate access.  
Similar mechanisms of PLC-ε regulation by Ras superfamily GTPases are readily 
envisioned; however, binding to Ras superfamily GTPases could also induce conformational 
changes in the catalytic site of PLC-ε not observed with PLC-β2 and Rac1. 
 Two decades ago, two groups independently suggested a role for Ras family proteins 
in the regulation of phosphoinositide metabolism [125;126].   The identification of PLC-ε as 
a direct and dual effector of Rho and Ras adds a new level of complexity to the role of Ras 
superfamily proteins in phospholipid signaling and metabolism. Because PLC-ε is 
cooperatively regulated by interactions with both Rho and Ras, we envision physiological 
scenarios in which PLC-ε activity is simultaneously activated by multiple GTPases resulting 
in increased phospholipid metabolism.  Future experiments will attempt to elucidate the 
spatial and temporal regulation of PLC-ε by multiple GTPase signaling pathways, as well as 
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 provide structural information regarding the molecular mechanisms by which Ras 
superfamily GTPases regulate the function of PLC-ε.    
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Figure 4.1.  RhoA and H-Ras activation of PLC-ε requires individual domains.  A, The 
specific PLC-ε constructs used and amino acid ranges are as follows: CDC25-Ct, 509-2281; 
CDC25-RA1, 509-2113; and EF-Ct∆Y, 1198-2281 lacking residues 1667-1728.  B, 
constitutively active mutants of RhoA (100 ng) or H-Ras (100 ng) were expressed in COS-7 
cells in the absence and the presence of the indicated PLC-ε constructs (50 ng each).  
[3H]Inositol phosphate accumulation was quantified as described under “Experimental 
Procedures” and [3H]inositol phosphate accumulation for each G protein in the absence of 
PLC-ε was subtracted from the corresponding samples expressing PLC-ε. Data shown are the 
mean ± S.D. for triplicate samples, and the results are representative of three or more 
experiments in each case.     
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Figure 4.2.  Dual activation of PLC-ε in cells overexpressing RhoA and H-Ras.  Full-
length FLAG-PLC-ε was expressed alone in COS-7 cells, or expressed in the presence of 
RhoA (100 ng) and H-Ras (100 ng) individually or in combination.  The amounts of DNA 
used were optimized to give maximal PLC-ε-dependent stimulation for each individual 
GTPase. [3H]Inositol phosphate accumulation was quantified as described under 
“Experimental Procedures” and [3H]inositol phosphate accumulation for each G protein in 
the absence of PLC-ε was subtracted from the corresponding samples expressing PLC-ε.  
Data shown are the mean ± S.D. for triplicate samples, and the results are representative of 
three or more experiments in each case.    
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Figure 4.3.  Specificity of G protein regulation of PLC isozymes.  A, monomeric GTPases 
were purified from detergent-extracted HighFive insect cell membranes as described under 
“Experimental Procedures.”  Purified RhoA (125 nM), K-Ras (125 nM), or Rac1 (125 nM) 
were reconstituted in phospholipids vesicles containing [3H]PtdIns(4,5)P2 and incubated with 
10 µM GDP (open bars) or 10 µM GTPγS (black bars) for 30 min at 30oC prior to the 
addition of PLC.  The assay was initiated by the addition of purified PLC-ε EF-RA2 (2 ng) 
and incubated at 30oC for 8 min.  B, purified PLC-β PH-C2 (5 ng) was added to phospholipid 
vesicles containing GDP-bound (open bars) or GTPγS-bound (black bars) RhoA (125 nM), 
K-Ras (125 nM), or Rac1 (125 nM).  Incubations were performed for 8 min at 30oC.  Inset, 
purified GTPases were resolved by SDS-PAGE and gells were stained with Coomassie blue.  
C, PLC-ε EF-RA2 or PLC-β PH-C2 was added to phospholipids vesicles in the absence 
(open bars) or resence (black bars) of purified Gβ1γ2 (100 nM).  The results presented are the 
mean ± S.E. of a representative experiment performed three times. 
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Figure 4.4.  Direct in vitro activation of PLC-ε by RhoA and K-Ras through distinct 
domains.  Wild-type PLC-ε EF-RA2 (left) or PLC-ε EF-RA2 (K2150E, K2152E) (right) 
were reconstituted in phospholipid vesicles containing [3H]PtdIns(4,5)P2 substrate.  Assays 
were performed in the absence of G-proteins (open bars) or in the presence of maximally 
activating concentrations of GDP-bound (dashed bars) or GTPγS-bound (black bars) RhoA 
(300 nM) or K-Ras (300 nM).  G-proteins were preincubated in the presence of 10 µM GDP 
or 10 µM GTPγS to allow nucleotide exchange.  The assay was initiated by the addition of 
PLC enzyme and incubations were for 8 min at 30oC.  Data are presented as the mean ± S.E. 
of an individual experiment representative of three individual experiments.  Inset, purified 
PLC-ε EF-RA2 proteins were resolved by SDS-PAGE and gels were stained with Coomassie 
blue. 
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Figure 4.5. Time course of PtdIns(4,5)P2 hydrolysis by purified PLC-ε.  The time 
dependent stimulation of purified, wild-type PLC-ε EF-RA2 (1 ng) was tested in 
phospholipid vesicles reconstituted with maximally activating concentrations (300 nM) of 
RhoA (orange closed upward triangles) or K-Ras (green closed downward triangles), or 
vesicles containing 300 nM of both RhoA and K-Ras (blue closed circles).  GTPases 
reconstituted in phospholipids vesicles were preincubated in the presence of 10 µM GTPγS 
prior to PLC addition for 30 min at 30oC to allow nucleotide exchange.  The activity of PLC-
ε ER-RA2 in the absence of G proteins is also represented (black closed squares).  The 
ability of GDP-bound RhoA (orange open upward triangles), K-Ras (green open downward 
triangles), or RhoA and K-Ras (blue open circles) to regulate PLC-ε EF-RA activity are 
represented at the 6 min time point The results presented are representative of five individual 
experiments and are presented as the mean ± S.E. 
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Figure 4.6.  Direct dual  and independent regulation of PLC-ε by purified RhoA and K-
Ras.  A, increasing concentrations of RhoA were reconstituted in phospholipid vesicles 
containing [3H]PtdIns(4,5)P2 in the absence (open circles) or presence of 300 nM K-Ras 
(closed circles).  After a 30-minute preincubation of RhoA or RhoA/K-Ras containing 
micelles in the presence of 10 µM GTPγS, PLC-ε EF-RA2 (2 ng) was added and the 
incubation was continued for 8 min at 30oC.  B, increasing concentrations of K-Ras were 
reconstituted in phospholipid vesicles in the absence (open circles) or presence of 300 nM 
RhoA (closed circles).    Assay was performed for 8 min at 30oC.  Purified PLC-ε EF-RA2 
was added to phospholipid vesicles containing maximally activating concentrations of RhoA 
and K-Ras preloaded with GDP (asterisk). 
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  TABLE 4.1 
       RhoA and K-Ras promoted activation of PLC-ε 
 
 
 
 
 
 
 
 
 
 
 
 
 
                     
 
 
                    * Concentration effect curves generated in the presence of 300 nM of the  
                          noted GTPase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
  
Rate              
(pmol/min) 
EC50            
(nM) 
PLC-ε EF-RA2 12.2 ± 2.1  
   
    + RhoA 29.8 ± 0.9 21.3 ± 3.4 
    + RhoA + K-Ras* 44.3 ± 1.1 19.3  ± 0.5 
   
    + K-Ras 29.3 ±  1.2 14.9 ±  2.6 
    + K-Ras + RhoA* 45.8 ±  0.8 5.6 ±  0.7 
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 CHAPTER 5 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
  
 All signal transduction pathways regulating the action of PLC isoforms result in the 
depletion of PtdIns(4,5)P2 and the generation of second messenger molecules.  Whereas PLC 
activation was once thought to simply occur downstream of heterotrimeric G proteins or 
tyrosine kinase phosphorylation, emerging mechanisms of PLC regulation and the 
identification of novel PLC isoforms suggest common, yet specific roles for individual PLC 
isoform activation.  Measuring inositol phosphate accumulation in cells overexpressing PLC 
isoforms is a powerful tool for identifying potential mechanisms of enzyme regulation; 
however, this method is not without limitations.  Coexpression studies are useful for 
identifying protein involved in signaling pathways that regulate PLC activity, but these 
assays cannot unambiguously demonstrate the regulation of PLC enzymes via direct protein-
protein interactions.  In vitro reconstitution of purified protein components circumvents some 
of the pitfalls of cell-based systems for studying PLC regulation, but also requires the ability 
to purify sufficient amounts of soluble, active protein.  To this end, we have purified and 
characterized a catalytically active fragment of PLC-ε encompassing the EF-hand repeats 
through the second RA2 domain (Chapter 2).  The purified enzyme displayed characteristics 
shared among all PLC isoforms, and more importantly, allowed us to identify PLC-ε as a 
direct effector of activated RhoA (Chapter 3).  These data, combined with previous 
experiments [147], have provided definitive evidence for the regulation PLC-ε activity 
 downstream of activated GPCRs coupled to Gα12/13, the activation of Rho-family GEFs, and 
the subsequent activation of Rho GTPases.   
My experiments have also helped to resolve conflicting studies concerning Ras-
regulated PLC-ε activation by showing the direct, RA2-dependent regulation of PLC-ε by 
purified Ras family GTPases (Chapter 4).  The regulation of PLC-ε activity by Rho and Ras 
family proteins through interactions with distinct regions of the enzyme directed us to 
explore the potential dual regulation of PLC-ε by both Ras subfamilies.  Indeed, my 
experiments show that when PLC-ε is activated by a maximally activating concentration of 
either RhoA or K-Ras, enzyme activity is increased even further by the addition of the 
complementary GTPase.  Herein, we have identified one of the first enzymes directly 
regulated by two different subclasses of Ras superfamily GTPases.  Another well 
characterized effector of both Ras and Rho family GTPases are the class I PI3Ks, which are 
activated by both Ras and Rac GTPases; however, these GTPases regulate activity through 
interactions with distinct subunits of PI3K [245;246].  The future aims of this research are to 
continue to define the molecular basis of PLC-ε regulation by Rho and Ras family GTPases 
with the ultimate goal of understanding the mechanisms whereby various GTPases 
individually and cooperatively regulate PLC-ε activity. 
 Whereas transient transfection of cells limits the ability to detect direct protein-
protein regulation of PLC enzymes, reconstitution experiments fail to address the biology 
associated with PLC activation in vivo.  For instance, although in vitro experiments suggest 
PLC-ε is regulated individually and dually by Rho and Ras family GTPases, these 
experiments do not address the physiological consequences of PLC-ε regulation by various 
GTPases.  Dual regulation of PLC-ε by both Rho and Ras GTPases would allow intricate 
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 spatial regulation of PtdIns(4,5)P2 hydrolysis at cellular localizations where both GTPases 
were activated.  Coexpression of PLC-ε with RhoA and H-Ras in COS-7 cells suggests a 
similar additive increase in enzyme activity observed in vitro.  However, it is not known if 
the observed increased phospholipase activity is due to varied localization of PLC-ε to 
multiple intracellular membranes, or if RhoA and Ras cooperate at the same intracellular 
membranes to regulate PLC-ε activity.  To address this issue, immunohistological detection 
of PLC-ε could be used to visualize PLC localization after overexpression with constitutively 
active RhoA, various Ras proteins, or Rho and Ras proteins.  Localization of PLC-ε at 
similar membranes in the presence of Rho and/or Ras proteins would suggest dual regulation 
of PLC-ε occurs in a physiologically relevant context.  Ras GTPases have been implicated as 
upstream regulators of Rho activation, suggesting Ras activation could potentially result in a 
transient increase in PLC-ε activity, followed by sustained PtdIns(4,5)P2 hydrolysis resulting 
from activation of Rho GTPases.  Live cell imagining could also be used to show the spatial 
and temporal regulation of PLC-ε in response to receptor mediated activation of Rho, Ras, or 
Rho and Ras in combination.  
 Defining the regions within PLC-ε necessary for interaction with various Ras 
superfamily GTPases, as well as the potential mechanisms by which G proteins stimulate 
PLC-ε enzyme activity are essential steps for ascertaining physiological consequences of 
these interactions.  Ras and Rho family proteins are involved in several mammalian 
physiologies including cell proliferation, cell differentiation, cytoskeletal changes, and 
vesicular trafficking.  An emerging role for Ras superfamily GTPases involves the regulation 
of phospholipid metabolism through the regulation of PI kinases and phospholipases.  The 
ability of Rho GTPases to regulate the function of PLC-ε could result in sustained calcium 
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 release and PKC activation as Rho GTPases also activate PI(4)P-5K.  Moreover, several 
proteins involved in actin polymerization and vesicular trafficking require PtdIns(4,5)P2 for 
activation, suggesting site specific Rho and Ras regulation of PLC-ε could negatively 
regulate pathways involved in cytoskeletal changes.  The oncogenic properties of mammalian 
Ras proteins, combined with Kataoka’s inactivated PLC-ε mouse model, suggests PLC-ε 
may be intricately involved pathways leading to cell proliferation and tumorgenesis.  Current 
studies in Dr. Channing Der’s lab are exploring the proliferative effects of hyperactive PLC-ε 
by expressing PLC-ε lacking the X-Y linker region.  As both Rho and Ras GTPases are 
involved in cell cycle progession, it would also be interesting to determine if PLC-ε-
dependent changes in phosphoinositide levels, calcium release, and/or PKC activation are 
involved in the ability of Ras superfamily GTPases to regulate cell cycle progression. 
 Although we have identified PLC-ε as a direct effector of GTP-bound RhoA, the site 
of RhoA interaction has yet to be delineated.  Sequence analysis does not identify regions of 
homology shared among other Rho family effectors, suggesting that determination of the 
Rho-binding site within PLC-ε will reveal a novel Rho-interacting motif.  Removal of a 
unique sequence within the Y-box of PLC-ε results in the loss of RhoA-mediated activation. 
However, GTP-dependent binding of RhoA to mutated PLC-ε was still observed using GST-
pulldown assays ([142], chapter 3).  Collectively, these experiments suggest the insert region 
of PLC-ε may be part of, or proximal to, the RhoA binding site within PLC-ε.  One method 
for identifying the sequence required for RhoA binding is to create short overlapping 
peptides corresponding to the sequence of PLC-ε.  This methodology was previously utilized 
by Sankaran and colleagues to identify the region PLC-β that interacts with Gβγ-subunits 
[247].  The peptides could be tested for the ability to block Rho-mediated PLC-ε activation in 
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 reconstitution experiments and the specificity of the peptides could be tested by showing 
inability to block K-Ras activation.  Additionally, peptides corresponding to the region 
within the RA2 domain of PLC-ε required for K-Ras activation, derived from the crystal 
structure provided by Bunney and colleagues [135], could be used as an experimental control 
and provide evidence regarding the feasibility of the proposed experiments. 
 The most significant future aim of these studies is to obtain structural information 
regarding the mechanisms by which Rho and Ras family proteins regulate the functional 
activity of PLC-ε.  Several attempts have been made to crystallize the fragment of PLC-ε 
used in functional experiments described throughout this research, but with little success.  
Regardless, the domains encompassed within the purified PLC-ε fragment remain the most 
intriguing crystallography targets as the EF-RA2 regions confer regulation by both Rho and 
Ras family GTPases.  Various constructs of other PLC isoforms (i.e. PLC-β2 PH-C2, full-
length PLC-γ1) have yielded significantly greater quantities of purified proteins, which may 
be possible for PLC-ε by redefining the amino acid boundaries encompassed by expression 
vectors.  For instance, including the PH domain, or the short sequence following the RA2 
domain, may aid in protein solubility resulting in increased yields of purified protein after 
overexpression in insect cells. 
 Definitive answers regarding the mechanisms of PLC-ε regulation require structural 
information obtained by comparing structures of PLC-ε isolated during different states of 
“activation.”  Based on experiments described throughout this work, there are several 
obvious targets for crystallography: (i) PLC-ε in the absence of activators, (ii) PLC-ε in 
complex with activated RhoA, (iii) PLC-ε in complex with one of several Ras GTPases, and 
(iv) PLC-ε in complex with both RhoA and Ras.  Perhaps the most beneficial crystal target is 
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 PLC-ε in the absence of an activator, which will provide evidence regarding the basal state of 
the enzyme to compare with structures of PLC-ε in complex with G protein activators.  
Although crystal structures of the catalytic core of two PLC isoforms have already been 
solved, the crystal structure of PLC-ε EF-RA2 will substantiate in vivo experiments 
suggesting the X-Y linker region of PLC-ε autoinhibits enzyme activity, and provide 
evidence to support our hypothesis that occlusion of the active site by the X-Y linker serves 
as a general mechanism to autoinhibit several, if not all, PLC isoforms.   
 Solving the crystal structure of PLC-ε in complex with RhoA will answer several 
questions regarding the regulation of PLC-ε by Rho GTPases, perhaps making this the most 
intriguing crystal target.  First, because the site of RhoA interaction is currently unknown, 
solving the crystal structure of a PLC-ε/RhoA complex will detail specific contacts made 
between the two proteins.  This will be especially important if scanning peptides produced 
for the experiments described above fail to identify the site within PLC-ε that binds RhoA.  
Secondly, because RhoA interacts within the catalytic region of PLC-ε, there is an increased 
probability that complex formation results in conformational changes within PLC-ε to confer 
increased enzymatic activity.  Moreover, because of the apparent autoinhibition of PLC-ε 
through occlusion of the active site by the X-Y linker, RhoA could potentially result in the 
relief of autoinhibition by binding to regions within or adjacent to the linker region of PLC-ε.  
Finally, the role of the “Y-loop insert” region in RhoA-regulated enzyme activity could be 
determined by comparing the structure of PLC-ε alone to PLC-ε in complex with RhoA.   
 Although the recent NMR and crystal structures of the RA domains of PLC-ε have 
provided detailed analysis regarding the interaction between the RA2 domain of PLC-ε and 
H-Ras, these data do not address the enzymatic consequences of the observed interaction 
116
 [135].  Based on their crystallographic and experimental data, Bunney and colleagues 
propose that the RA domains fold back on the catalytic region of PLC-ε resulting in 
autoinhibition of enzyme activity, which is relieved upon Ras binding and translocation of 
the enzyme to the plasma membrane.  Solving the crystal structure of PLC-ε alone and in 
complex with activated H-Ras would provide convincing evidence regarding the plausibility 
of this mechanism of PLC-ε regulation.  Alternatively, binding of Ras family proteins to the 
RA domains could simply recruit and tether PLC-ε to the plasma membrane, which would be 
supported by a crystal structure suggesting the RA domains are loosely tethered to the 
catalytic region of the enzyme.   
 The crystal structure of PLC-β2/Rac1 suggests association with Rac1 serves to 
localize PLC-β2 to the plasma membrane and position the enzyme in an orientation favorable 
for substrate hydrolysis.  However, complex formation between Rac1 and PLC-β2 does not 
result in significant conformational changes within the catalytic regions of the enzyme [71].  
Comparison of the PLC-β/Rac complex with PLC-ε/RhoA and/or Ras would provide 
significant information concerning the regulation of various PLC isozymes by Ras 
superfamily GTPases.  Whether PLC isozymes have evolved a collective affinity for Ras 
superfamily proteins to confer membrane localization, or if individual PLC isozymes are 
affected differently through interactions with G proteins will provide specific details on the 
mechanisms of Ras superfamily PLC activation.  
 Several mouse models have begun to identify physiologies associated with PLC-ε 
activity [154-156].  Mice expressing a catalytically inactive PLC-ε, or mice lacking the entire 
PLC-ε gene, exhibit various phenotypes.  However, the upstream signaling pathways 
mediating the various observed physiologies have yet to be determined.  Defining critical 
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 amino acids required for Rho and/or Ras interaction with PLC-ε will allow targeted mutation 
of PLC-ε at these amino.  Mutated PLC-ε constructs could be expressed in systems ranging 
from overexpression in COS-7 cells to mice expressing various mutated PLC-ε constructs, 
with the goal of defining the physiologies associated with signal-specific PLC-ε regulation.  
 Although PLC-ε research is relatively new within the field of PLC signaling, the 
efforts of several groups have made great strides in delineating pathways involved in PLC-ε 
enzyme regulation.  The ability to be regulated by such a large number of upstream signals 
places PLC-ε at the nexus of converging signaling pathways derived from both 
heterotrimeric and monomeric G protein signaling.  In addition to responding to several 
upstream signals, PLC-ε is unique among PLC isoforms operating as both an initiator and 
recipient of Ras GTPase signals, potentially leading to an autofeedback mechanism of 
regulation.  Given the increasing number of signaling pathways involved in the regulation of 
PLC-ε, it is probable that PLC-ε is critically involved in several mammalian physiologies.  
The studies presented here and the proposed future directions will contribute to the further 
understanding of unique pathways that regulate the activity of PLC-ε.           
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